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Abstract	  
 
Alzheimer’s disease is the most common cause of dementia affecting 5% of the population 
between 65-74 years and 50% over 80 years. Despite its increasing burden, there are 
currently no treatments available to stop or slow down the degeneration associated with 
AD. The therapies that are available merely alleviate the symptoms with minimal impact on 
disease progression.   
 
Neurotrophin dysfunction has been implicated in AD including the activation of the p75 
neurotrophin receptor (p75NTR) mediated neuronal death signalling. Our lab has been 
investigating the p75NTR cell death pathway for a number of years and has characterised 
a 29 amino acid intracellular juxtamembrane domain of p75NTR that is capable of 
preventing p75NTR mediated cell death in vitro. Due to the involvement of p75NTR death 
signalling in neurodegenerative diseases such as AD, any compound that inhibits the 
activation of p75NTR cell death signalling can be therapeutically beneficial.  
 
The goal of my research was to test the efficacy of this 29 amino acid domain peptide 
(biotin-TAT-c29) in vivo. In order to examine this, firstly we had to develop/characterize an 
animal model of degeneration. This study characterized three different models: i) SAMP8 
model of basal forebrain death, ii) neurotrophin dependent model of basal forebrain death 
and iii) Aβ mediated hippocampal toxicity model. Secondly, the protocol for the delivery of 
the peptide into the brain was optimized through both intraperitoneal injection and 
subcutaneous osmotic pumps. Finally, the ability of the biotin-TAT-c29 peptide to prevent 
degeneration was tested. We successfully characterised two possible models of 
degeneration to test the efficacy of the biotin-TAT-c29 peptide. We also established a 
robust protocol for the delivery and detection of the biotin-TAT-c29 peptide into the central 
nervous system. While the results from the final experiment involving the delivery of biotin-
TAT-c29 into a degeneration model were equivocal, other work from the lab indicates the 
promising therapeutic nature of this peptide suggesting that further studies should be 
pursued using biotin-TAT-c29. 	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Chapter	  1	  -­‐	  Introduction	  	  
1.1.	  Alzheimer’s	  disease	  	  
Alzheimer’s disease (AD) accounts for about 60-70% of all dementia cases and results in 
memory loss and decline in cognitive abilities (Holtzman et al., 2011).  Key hallmarks of 
AD include amyloid beta (Aβ) plaques, neurofibrillary tangles and extensive neuronal loss 
(Holtzman et al., 2011). There are three main hypotheses to explain the cause of the 
disease: the amyloid hypothesis, the tau hypothesis and the cholinergic hypothesis.  
 
The Amyloid Hypothesis of AD proposes that the accumulation and aggregation of Aβ 
within the brain is the primary cause of cognitive decline and degeneration seen in AD 
(Glenner and Wong, 1984, Masters et al., 1985, Hardy and Selkoe, 2002, Tanzi, 2005). Aβ 
is the product of beta (β) and gamma (γ) secretase cleavage of the amyloid precursor 
protein (APP). Most evidence for this hypothesis is based on familial cases of AD due to 
mutations in three key genes the Aβ precursor protein (APP) itself, Presenilin 1 and 2, the 
enzymatic component of γ-secretase (Hardy et al, 1995).	   These mutations result in 
overproduction of Aβ by enhancing the processing of APP to Aβ or by generating forms of 
Aβ that are particularly prone to aggregation and thus are neurotoxic	  (Hardy et al., 1998, 
Tanzi and Bertram, 2005).	  The	  Aβ42 isoform (that is 42 amino acids long) of Aβ is more 
prone to aggregation than the Aβ40 isoform, which gives rise to toxic dimers, oligomers 
and fibrils and ultimately to the production of plaques. 	  
The Tau Hypothesis of AD argues that neurofibrillary tangles are the primary cause of AD 
(Lee et al., 2001b). The tangles are comprised of microtubule-associated protein called 
Tau which is normally expressed in axons. During AD, Tau protein becomes 
hyperphosphorylated and aggregates into abnormal fibrillary filaments in the cell body 
resulting in microtubule disintegration and collapse of the neuronal transport system 
eventually leading to neuronal death (Mudher and Lovestone, 2002, Iqbal et al., 2005, 
Chun and Johnson, 2007). However, no mutations have been reported in the Tau gene 
that result in AD. Rather, more recent evidence has suggested Tau pathology to be 
downstream of Aβ pathophysiology (Ittner and Gotz, 2011). Taken together with the strong 
support for the amyloid hypothesis in mouse models where overproduction of Aβ results in 
cognitive deficits, the findings argue Aβ to be the proximal cause of AD as opposed to Tau. 
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However, phosphorylated-tau could be acting together with Aβ to mediate neuro-toxicity 
(Gotz et al., 2011, Ittner and Gotz, 2011). 	  
The Cholinergic Hypothesis proposes that cognitive decline seen in AD is in response to 
the degeneration of cholinergic basal forebrain (cBF) neurons (Bartus et al., 1982). The 
cholinergic basal forebrain refers to the area of the brain derived from the subpallium and 
located close to the medial and ventral surfaces of the cerebral hemisphere. It comprises 
of different nuclei including the medial septum (MS), vertical and horizontal diagonal bands 
(VDB and HDB) nucleus basalis and substantia innominata. The release of acetylcholine 
from innervating cBF neurons normally regulates the excitability and plasticity of 
neocortical areas, which in turn controls higher order cognitive functions such as attention, 
learning and memory (Coyle et al., 1983, Sarter and Bruno, 2004). Therefore, the 
degeneration of cBF neurons results in the loss of this cholinergic neurotransmission in the 
cerebral cortex, hippocampus and other areas that play a significant role in learning and 
memory (Bartus et al., 1982, Terry and Buccafusco, 2003). In AD, 75% of cBF neurons are 
selectively lost coincident with frank loss of presynaptic cholinergic markers throughout the 
cortex (Whitehouse, 1991a, b). The hypothesis that loss of acetylecholine to the cortex 
underpins the cognitive decline seen in AD served as the basis for the main therapeutic 
approaches that currently exist for AD.  
 
The cholinergic basal forebrain neurons are highly dependent on neurotrophin survival 
signalling throughout life. Nerve growth factor (NGF) is the principal target derived 
neurotropic factor that not only protects cBF neurons from insults and age dependent 
atrophy but also potentially regulates their phenotype and plasticity (Brooks et al., 2000a). 
TrkA receptor for NGF mediates signal transduction pathways important for promoting and 
maintaining synaptic contact with cortical and hippocampal neurons and for cBF neuron 
survival. An imbalance in this signalling due to reduced levels of NGF and/or TrkA 
observed in AD subjects at post-mortem, can impact memory formation and neuronal 
degeneration (Mufson et al., 1997, Capsoni et al., 2000). This forms the basis for the 
neurotrophic hypothesis which states that a dysfunction of neurotrophin survival signalling 
is responsible for the degeneration of cholinergic neurons in Alzheimer's disease.	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1.2.	  Neurotrophins	  in	  AD	  
Neurotrophins are a family of growth factors that play important roles in both the 
developing and adult brain to regulate neuronal survival and death. Four neurotrophins 
that exist in a mammalian brain include NGF, brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) (Dechant and Barde, 2002, Underwood 
and Coulson, 2008, Skeldal et al., 2011). Neurotrophins exhibit their vast range of 
functions via two structurally different receptors: the tropomyosin receptor-like kinase (Trk) 
receptors and the p75 neurotrophin receptor (p75NTR) (Hennigan et al., 2007). While the 
signalling pathways activated by the Trk receptor family are well characterized in the 
literature as predominantly trophic, p75NTR can mediate a range of signalling outcomes. 
 
Originally, p75NTR was known to act as a co-operative facilitator of the Trk receptors by 
forming a high affinity NGF receptor complex (Hempstead et al., 1991). This results in 
activation of survival signalling to allow cell proliferation, migration, neurite 
elongation/retraction and synaptic transmission in response to minimal amounts of NGF 
available in vivo (Davies, 1991, Barker, 2004). However, later it was demonstrated that the 
receptor could signal cell death in the absence of appropriate Trk activation (Coulson et 
al., 2000b, Dechant and Barde, 2002, Coulson et al., 2009). Pro-neurotrophins are the 
precursor form of the mature neurotrophins and have been exclusively shown to promote 
cell death via the p75NTR both in the presence and absence of Trk receptors (Skeldal et 
al., 2011).  
 
In the developing nervous system, p75NTR is widely expressed in the central nervous 
system where it regulates synaptogenesis and developmental cell death (Davies, 1991). 
The expression of p75NTR is down regulated post development in most brain regions. 
However, some pathological conditions like mechanical damage, focal ischemia, epilepsy, 
axotomy and neurodegenerative disorders such as AD can result in re-expression of 
p75NTR at levels comparable to that during development, and can signal neuronal death 
(Lowry et al., 2001).  
 
Interestingly, the cBF neurons continue expressing p75NTR throughout adult life. cBF 
neurons project their axons to the hippocampus and cortex which produce the survival-
promoting  on which cBF neurons are dependent on for survival (Coulson et al., 2000b, 
Ginsberg et al., 2006). The role of p75NTR in cBF neurons may either be: strengthening 
cBF neuron innervations (to their target neurons by facilitating Trk mediated trophic 
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signalling) or pruning neurons that do not receive sufficient trophic support (Naumann et 
al., 2002). Enhancing NGF expression in the cBF either exogenously or via repetitive 
learning tasks results in an augmentation of synaptic function and memory due to an 
increase in cBF neuron innervations to the cortex (Brooks et al., 2000a, Brooks et al., 
2000b, Prakash et al., 2004). In contrast, a reduction in NGF supplied to the cBF lowers 
the density of cBF neuron innervations to their targets therefore reducing synaptic 
plasticity (Gutierrez et al., 1997). These changes associated with varying NGF levels 
signify the importance of TrkA and p75 signalling in the maintenance of cBF. 
 
Cognitive changes occurring in AD could be due to the dysfunction of the neurotrophin 
signalling in the basal forebrain, as decreased levels of NGF and TrkA have been reported 
in AD patients (Mufson et al., 1992, Fahnestock et al., 2001, Ginsberg et al., 2006). 
Furthermore, in AD the levels of cell death-inducing pro-neurotrophins and p75NTR are 
up-regulated, shifting the balance of neurotrophin survival signalling to death signalling 
and resulting in reduced cBF neuron number and subsequently facilitating degeneration of 
the denervated cortical and hippocampal neurons (Nagappan and Lu, 2005). 
 
In animal models of neurodegeneration, including AD, blocking p75NTR signalling has 
been shown to prevent cell death, highlighting the importance of p75NTR as a candidate 
therapeutic target (Sotthibundhu et al., 2008, Yang et al., 2008, Knowles et al., 2009). 
Being able to interfere with the ability of p75NTR to signal neuronal death, or enhancing 
p75NTR-facilitated Trk survival signalling may be highly beneficial in promoting neuron 
survival in a number of p75NTR-mediated neurodegenerative disorders. 
1.3.	  A	  juxtamembrane	  domain	  peptide	  of	  p75NTR	  as	  a	  neuroprotectant	  
1.3.1	  Regulation	  of	  p75	  survival	  and	  death	  signalling	  functions	  
The opposing survival and death functions of p75NTR described above can be partially 
explained by the receptor’s ability to undergo regulated proteolysis. p75NTR can signal 
constitutively in the unbound and monomeric state as a result of regulated intramembrane 
proteolysis whereby the extracellular domain (p75NTR-ECD) is cleaved by an α-secretase 
(ADAM17/TACE). This results in a membrane tethered C-terminal fragment (CTF), which 
undergoes subsequent cleavage by the presenilin-dependent γ-secretase releasing the 
intracellular domain (p75NTR-ICD) fragment into the cytoplasm (Lee et al., 2001a, Jung et 
al., 2003, Kanning et al., 2003).  
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It has previously been shown by the Coulson laboratory that the membrane bound 
p75NTR-CTF induces cell death whereas the p75NTR-ICD fragment, free in the cytosol 
facilitates survival signalling (Coulson et al., 1999, Coulson et al., 2000a, Underwood et 
al., 2008). Our lab has also found that the p75NTR-ICD can promote survival signalling 
through interacting with Trk receptors (Ceni et al., 2010, Kommaddi et al., 2011, Matusica 
et al., 2013). Others have also reported that the p75ICD fragment can promote survival 
signalling (Ceni et al., 2010, Kommaddi et al., 2011) as well as, neurite outgrowth, 
differentiation and cell death (Frade, 2005; Kenchappa et al., 2006; Bronfman, 2007; 
Skeldal et al., 2011). These findings suggest that the cleavage of p75NTR ectodomain is 
necessary for the physiological activation of p75NTR  (Skeldal et al, 2011). 
 	  
 
 
 
 
 
 
 
 
 
	  
	  
Figure	  1.1-­‐	  Schematic	  of	  p75NTR	  cleavage	  
The full-length p75NTR undergoes intramembranous proteolysis mediated initially by the α -
secretase releasing the ECD fragment. The C-terminal fragment (CTF) attached to the membrane 
has been shown to promote cell death even in the absence of ligand. A γ-secretase subsequently 
cleaves CTF, liberating an intracellular domain fragment (ICD). c29 (indicated in red) is the 29 
amino acid fragment of the juxtamembrane domain. 
 
A key discovery underpinning the Coulson lab discovery of opposing roles for the p75NTR 
fragments was the identification and characterisation of the Chopper domain of p75NTR 
(Coulson et al., 1999, Coulson et al., 2000a). This juxtamembrane domain comprises a 29 
amino acid sequence (KRWNSCKQNKQGANSRPVNQTPPPEGEKLHSDSGI). When 
tethered to the membrane this peptide (c29) promotes cell death, however when 
unattached to the cell membrane the peptide inhibits cell death (Coulson et al., 2000a, 
Matusica et al., 2013). The ability of c29 to inhibit neural death suggested a dominant-
p75NTR-­‐ECD	  
p75NTR-­‐ICD	  
p75NTR-­‐CTF	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negative mechanism whereby both the membrane bound and unbound forms were 
interacting with the same accessory proteins. p75NTR-CTF when free in the cytosol may 
also be able to sequester these proteins and inhibit their action thereby contributing to the 
dominant negative signalling of p75NTR (Coulson et al., 2000a, Coulson et al., 2004).  
 
However, recent work from the lab that aimed to understand the exact mechanism by 
which c29 mediates its action revealed the ability of c29 to interact with TrkA and TrkB 
receptors. The experiment, to which I contributed, involved immunoprecipitation of the Trk 
receptors with a biotinylated c29 peptide. The immunoprecipitated complex was then 
detected using the receptor specific antibodies. While both TrkA and TrkB could be 
immunoprecipitated, the epidermal growth factor (EGF) receptor, a tyrosine kinase 
receptor with homology to the Trk receptors, did not associate with c29 (Matusica et al, 
2013). 
 
 
 
     
 
	  
Figure	  1.2	  -­‐	  c29	  interacts	  with	  Trk	  A	  and	  Trk	  B	  but	  not	  EGFR	  receptor	  	  
The western blot shows an immuneprecipitation experiment. Biotinylated c29 peptide was used to 
precipitate TrkA, TrkB and EGFR from cell lysates. The figure shows that c29 can 
immunoprecipitate with Trk A (HEK293 cells transfected with the TrkA receptor) and Trk B (NSC34 
cells that endogenously expressing the Trk B receptor). There was no interactions seen with 
scrambled c29 and c29 does not immunoprecipitate with the EGFR receptor (Matusica et al., 
2013). 
 
The c29 peptide also enhances NGF binding to TrkA receptor resulting in a 3-fold increase 
in receptor association rate as well as an increase in the number of receptor sites capable 
of binding NGF (Matusica et al., 2013). It is therefore postulated that c29 could be acting 
as an allosteric modulator of the Trk receptors and potentiating neurotrophic signalling by 
creating high affinity neurotrophin binding sites to promote survival signalling instead, or as 
a dominant negative inhibitor of death signalling (Matusica et al., 2013). Either function 
would make c29 a therapeutic agent to block p75NTR mediated cell death in 
neurodegenerative diseases like AD where neurotrophin signalling is compromised.  
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1.3.2	  Neuronal	  protection	  by	  c29	  
Study of the c29 peptide has been a focus of Coulson and colleagues for many years. It 
has been demonstrated that c29 inhibits p75NTR-mediated death signals during naturally-
occurring developmental cell death in the chick eye (Coulson et al., 2000a), protects 
sensory and motor neurons from growth-factor withdrawal-induced cell death in vitro and 
injury- and amyotrophic lateral sclerosis -like disease-induced cell death of motor neurons 
in vitro and in vivo (Matusica et al., submitted). One example of its effect in vivo is an 
axotomy experiment. After axotomy 50% of cervical motor neurons of new-born rats die 
because they no longer receive BDNF from their target muscle. When a c29-peptide was 
placed at the axonal stump of the rat pups, it protected motor neurons, as assessed 5 
days later (~10% cell death compared to ~50% p<0.01). These experiments suggest the 
c29 peptide has both a novel therapeutic property and in vivo efficacy to promote neuronal 
survival in conditions of neurotrophin signalling imbalance. 
 
Altered neurotrophin signalling in AD is not only caused by an altered expression of the 
neurotrophins and their receptors but also by the presence of Aβ. Aβ is known to be a 
ligand for p75NTR providing a possible mechanism via which Aβ toxicity in AD may be 
mediated (Yaar et al., 1997, Coulson et al., 2008, Sotthibundhu et al., 2008, Yang et al., 
2008, Knowles et al., 2009). The Coulson colleagues have additionally shown that Aβ can 
inhibit γ-secretase cleavage of the p75NTR, thereby promoting cell death through 
p75NTR-CTF and preventing participation of p75NTR-ICD in Trk mediated survival 
signalling (Sotthibundhu et al., 2008). Moreover, a former PhD student (Linda May, 
Manuscript submitted, 2014) found that the addition of c29 peptide to E16.5 hippocampal 
cultures blocked the toxic effects of Aβ42 (Fig 1.3). 
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Figure	  1.3	  -­‐	  c29	  blocks	  Aβ	  mediated	  death	  in	  hippocampal	  neurons	  
E18 hippocampal cultures were grown in the presence of Aβ and c29. Cell counts were performed 
to determine rates of survival over the 24 hours. Addition of Aβ42 to primary hippocampal neuron 
culture results in the survival of only 30% of cells. When c29 is added together with Aβ42, the 
survival of these neurons was significantly increased to 55%, a survival rate not significantly 
different from control-treated cultured ~60%) This protective effect is not seen with the scrambled 
control peptide	  (May et al, 2013 – manuscript submitted). 
 
In summary, the neurotrophins can influence the survival signalling of cBFNs as well as 
impact the production of toxic Aβ. The evidence for the neuroprotective ability of c29 
peptide has been shown both in the context of growth factor withdrawal and in conditions 
of neurotroxic Aβ42. As reduced supplies of neurotrophins and Aβ toxicity are two key 
pathophysiological features of AD the aim of this project was to test the efficacy of c29 
peptide in in vivo models of Alzheimer’s disease.  
1.4.	  Existing	  mouse	  models	  of	  Alzheimer’s	  disease	  
In order to better understand the pathophysiology of AD a number of experimental animal 
models have been established. Mouse models based on genetically manipulating 
particular gene function and expression allow us to study the function and affects of the 
resulting proteins and their involvement in disease conditions. In addition, the use of mice 
allow behavioural studies for examination of cognitive abilities (e.g. the clinical phenotype 
of AD) and are the predominant preclinical organism for screening of candidate drugs.  
 
The most widely used mouse models of AD are based on the transgenic expression of 
human APP cDNA (hAPP). A number of transgenic hAPP mouse lines exist, for example: 
i) PDAPP mice expresses hAPP 770 isoform with Indiana mutation (V717F), which 
	   19	  
exhibits Aβ plaque pathology at 2 years of age and a decrease in synaptic and dendritic 
density in the hippocampus without any neuron loss (German et al., 2003) ii) the Tg2576 
mouse model is generated by the overexpression of hAPP695 construct that contains a 
double Swedish mutation (K670N/M671L). These mice express 5-6 times more hAPP, 
exhibit plaque deposition at 9-12months of age, but again show no neuron loss (Sturchler-
Pierrat et al., 1997). iii) APP23 mice express APP Swedish mutation under the control of 
Thy1 promoter and show a decrease in cholinergic fibre density at 24 months of age but 
no loss of cBF neurons (Boncristiano et al., 2002). In general the hAPP transgenic models 
exhibit synaptotoxicity but fail to show any neuron loss.  
 
Presenilin mutations have also been used to develop AD mouse models. However, it was 
noted that a single presenilin mutation in mice did not result in AD like pathology due to 
differences between the mouse and human APP/Aβ (Selkoe, 1989, Holcomb et al., 1999). 
Combination of the presenilin mutation with hAPP mutation however results in accelerated 
AD pathology with mice exhibiting extensive plaque pathology and behavioural deficits 
(Duff et al., 1996, Jankowsky et al., 2004). The most commonly used line combines 
transgenes expressing hAPP with the Swedish mutation and presenilin 1 containing a ΔE9 
mutation. These mice develop amyloid plaques and cognitive deficits at 6-7 months of age 
(Jankowsky et al., 2004). While dystrophic cholinergic neurites with a significant reduction 
in cholinergic fibres in the cortex and hippocampus can be seen, these mice also do not 
exhibit any significant neuron loss (Perez et al., 2007).  
 
Many transgenic APP models of AD are reliably able to replicate the Aβ pathology seen in 
human condition but fail to recapitulate tau pathology. Similarly, most tau transgenic mice 
do not exhibit Aβ pathology. Therefore, most tau mutation models of AD are in conjunction 
with the hAPP models, as tau mutations alone do not cause AD (Oddo et al., 2003). A 
well-characterised model of AD incorporating tau mutations and Aβ overproduction is the 
3xTg model of AD which combines mutant hAPP, PS1 and tau transgene. Mice of this 
strain develop plaques and subsequent neurofibrillary tangles as seen in human AD (Oddo 
et al., 2003).  
 
While all the models described above have been useful for the particular purpose for which 
they were created, none of the models encompass all the pathology and cognitive deficits 
seen in human AD. Primarily, there is a lack of robust cholinergic cell loss in the basal 
forebrain suggesting that the current familial models of AD do not replicate the sporadic 
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disease pathology in terms of neuron loss (Perez et al., 2005). Therefore in order to test 
the therapeutic potential of c29 peptide in an Alzheimer’s disease model, an animal model 
that encompasses basal forebrain loss and Aβ toxicity first needed to be developed.  
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Hypothesis	  and	  Aims	  	  
We hypothesise that the intracellular domain peptide of p75NTR (c29) will prevent 
neuronal degeneration and cognitive changes in animal models of Alzheimer’s disease 
 
Aim 1: to develop a model of neuronal degeneration in mice where the efficacy of c29 in 
preventing the degeneration can be tested. Three possible models would be investigated: 
(i) Senescence accelerated model of cBF degeneration – Characterizing this 
mouse model for basal forebrain death 
(ii) Neurotrophin withdrawal model of cBF degeneration - Develop a model of 
neurotrophin dependent basal forebrain death by ablating the laterodorsal 
tegmental (LDT) neurons using the Urotensin-II saporin toxin 
(iii) Aβ hippocampal degeneration model – Develop a model of Aβ induced 
hippocampal degeneration by killing cBF with p75NTR-saporin toxin in double 
transgenic APP/PS1 mice  
 
Aim 2: to optimize a protocol for systemic delivery and detection of c29 in vivo  
 
Aim 3: to investigate the efficacy of c29 peptide in preventing neuronal degeneration in 
one or more of the mouse models developed in aim 1. 
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Chapter	  2	  -­‐	  Methods	  
2.1.	  Animals	  	  
All mice were housed in QBI animal facility under standard conditions with 12-hour 
light/dark cycle, controlled temperatures and humidity, food and water ad libitum with 
bedding and tissues for nesting. All animal experiments were carried out with the approval 
of the University of Queensland Animal Ethics Committee, which abides by the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes and the Animal 
Care and Protection Act (Qld) 2001. All efforts were made to minimize the number of 
animals used and their suffering.  
2.1.1.	  C57bl/6j	  	  
For all biotin-TAT-c29 delivery optimization experiments (Aim 2), male C57Bl/6J mice 
between the ages of 10-12 weeks were used. C57bl/6j mice were also used for the 
neurotrophin withdrawal model of degeneration (Aim 1b). For this model, surgeries were 
performed on males of age 7-8weeks, weighing between 20-24g. 
2.1.2.	  APP/PS1   
APP/PS1 is a double transgenic strain of mice (maintained on c57 background) expressing 
mutated human amyloid precursor protein (huAPP695swe) and a mutant human presenilin 
1 (PS1-dE9) mutation. The mutant human amyloid precursor protein consists of 
humanized mouse Aβ precursor protein gene which is modified at three amino acids as 
well as a mutation at K595N/M596L which is linked to familial AD. The PS1 transgene 
expresses a mutant form of the human presenilin 1 gene with a deletion at exon 9, which 
is also linked to familial AD. Both mutations result in an early onset of Alzheimer’s disease 
in these mice.  The mice were used for surgeries (Aim 1c) age between 2-5months. 
2.1.3.	  SAMP8	  	  
The senescence–accelerated prone mouse is an accelerated model of aging which was 
developed by selective inbreeding of the AKR/J strain of mice. These mice show age-
related behavioural deficits in learning and memory, anxiety, impaired immune system, 
and age dependent Aβ deposition. These mice were used for histological analysis (Aim 
1a) from age 3-12 months.  
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2.2.	  Peptide	  synthesis	  
The juxtamembrane domain of p75NTR (‘chopper’), which comprises of 29 amino acids 
(KRWNSCKQNKQGANSRPVNQTPPPEGEKL) was conjugated to a trans-activating 
transcriptional activator (TAT) protein transduction domain (PTD: YARAAARNARA) by 
Auspep Pty. Ltd (Tullamarine, Aus). A control peptide with a randomly scrambled 
sequence of the c29 peptide (SC: SKGQVCRNQPGQNKPEPANKSWKETPLRN) coupled 
to PTD was also synthesised. These peptides were labelled at the amino terminus with a 
biotin tag via a six-carbon spacer to allow detection of the peptides. The peptides were 
stored at 4oC in powder form and were reconstituted in sterile saline for in vivo 
experiments and MilliQ H2O for in vitro experiments prior to use.  
 
2.3.	  In	  Vivo	  systemic	  administration	  of	  c29	  
All animals weighed between 24g-30g and were randomly assigned into each group. The 
weight and general health of mice was monitored until sacrifice. Once sacrificed, the 
delivery of the peptide into the central nervous system was detected either by western 
blotting or immunohistochemistry of brain and spinal cord tissue. 
2.3.1.	  Intraperitoneal	  delivery	  
Mice were injected intraperitoneally with 100µl of biotin-TAT-c29 or control peptide made 
in sterile saline. For the pilot experiment mice (n=6) were injected with 2mg/kg c29 peptide 
and were sacrificed at either 1hr, 6hr, 24hr or 72hrs post injection. Mice were also injected 
at one-day interval for 6 weeks at 2mg/kg, 5mg/kg and 8mg/kg (n=3 per concentration).  
2.3.2.	  Subcutaneous	  delivery	  
Peptide delivery was also optimized using subcutaneous osmotic minipumps (Alzet 
corporation, Palo Alto, CA). For the pilot experiment, two 7-day pumps (Model 1007D with 
flow rate of 0.5µl/hr) were filled with 100µl of 8mg/kg biotin-TAT-c29 peptide and placed in 
sterile PBS at 37oC for 3 hours in order to initiate the pump. The mice were then 
anaesthetised using 5% isofluorane. Once the mouse was anesthetised, the head was 
cleaned with ethanol and an incision was made over the scalp. A curved haemostat was 
inserted from this incision in order to break the membranes under the skin and to create a 
pocket which would hold the pump. Once this pocket was made, the osmotic pump was 
inserted and placed behind the neck. After surgery, the mouse received a dose of 
analgesic (Torbugesic,1.3mg/kg) and antibiotic (Baytril, 0.43mg/kg). The mice were 
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sacrificed one week after the surgery and the results were compared to mice 
intraperitoneally injected with biotin-TAT-c29. 
2.4.	  In	  Vitro	  experiments	  with	  c29	  
2.4.1.	  ERK	  activation	  	  
PC12 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% foetal calf serum (FCS), 5% horse serum and 1% Glutamax. Cells were grown in 
a humidified 37oC incubator with 5% CO2 atmosphere. For the ERK activation assay, cells 
were plated in a 6-well plate poly-L-ornithine (0.015%) coated plates at 0.5 million 
cells/well and incubated overnight till confluent. Following day, the cells were serum 
starved in serum free media comprised of DMEM, 1% Glutamax and 1% non-essential 
amino acids for four hours at 37oC. An hour before lysis, some wells were treated with 
1µM of biotin-TAT-c29 peptide and incubated. Ten minutes before lysis, the cells were 
treated with different concentration of NGF. The following NGF treatment conditions were 
used: 0ng/ml (control), 1ng/ml, 10ng/ml, 100ng/ml, 1ng/ml + c29 and 10ng/ml + c29. Cells 
were incubated with NGF for 10 minutes to initiate an ERK response before they were 
lysed.  
2.4.2.	  Lysis,	  Immunoprecipitation	  and	  Western	  Blotting	  
After intraperitoneal injection of the peptide, brain and spinal cord were harvested. Total 
protein was extracted by lysing the tissue in TNE buffer (20 mm Tris, pH 8, 10 mm EDTA) 
supplemented with 1% Nonidet P-40 and complete protease inhibitor mixture (Roche 
Applied Science). The lysates were homogenised in the tissue homogeniser using 
magnetic beads for 3 minutes. The crude homogenate was centrifuged at 14000x g for 15 
minutes at 4oC. The supernatant was removed and spun for another 10 minutes.  
 
To perform protein immunoprecipitations, the lysates were incubated with Dynabeads 
MyOne Streptavidin T1 (Invitrogen), 2% Bovine Serum Albumin (BSA) and PBS overnight 
at 4oC to allow interactions between the biotinylated peptide and streptavidin. The 
immunocomplexes were then thoroughly washed (5 times) with Tris Buffered Saline (TBS; 
10 mM Tris pH 8.0, 150 mM NaCl) supplemented with 0.05% Tween 20 to prevent non-
specific binding. The samples were eluted in reducing sample buffer (20mM Dithiothreitol, 
2.5% SDS). For western blotting the samples were boiled at 95oC for 5 minutes and then 
subjected to reducing conditions on 12% SDS-PAGE gels (Invitrogen) for 90 minutes at 
130V. The proteins were transferred onto a nitrocellulose membrane at 90V for 90 
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minutes. The membrane was blocked in TBS-Tween  (TBST; 10 mM Tris, pH 8.0; 150 mM 
NaCl; and 2% Tween 20) supplemented with 5% (w/v) dried skim milk powder for 1 hour at 
room temperature. The membrane was probed for biotin-TAT-c29 peptide with primary 
rabbit anti-human p75NTR intracellular antibody (9992: used at concentration 1:1000, 
binding resides 276-399 (Huber & Chao, 1995)) overnight at 4oC or 3 hours at room 
temperature. This was followed by 3 times 10 minute TBS-T washes and incubation with 
anti-rabbit Alexa 680 (1:50,000, Bio-Red) secondary antibody for 45 minutes at room 
temperature. Membranes were washed again and were imaged for protein visualization 
using an Odyssey (LI-COR) imaging system.  
2.5.	  Stereotaxic	  Surgery	  
All mice that underwent the stereotaxic injections were weighed and anaesthetised using a 
mixture of ketamine (130mg/kg; Ketapex; Apex Laboratories, Sydney, Australia) and 
muscle relaxant xylazine (6mg/kg; Rompun; Bayer, Sydney, Australia). Once anesthetised 
the mouse was placed on the stereotaxic apparatus (Model 900; Kopf, Tujunga, CA, USA) 
with the incision bar maintained at -3.3mm below horizontal to allow for flat skull 
placement. The area where the incision was made was cleaned with an antiseptic 
betadine.  
 
For intracerebrovascular (ICV) injections, the needle was lowered into the lateral ventricles 
at co-ordinates: A-P 0.0mm; M-L ± 1.0mm; D-V -2.2mm from Bregma. Mice were divided 
into two groups for each of the two surgery models where they either received a control 
toxin rabbit-IgG-saporin (0.4µg/ventricle; Advanced Targeting Systems, San Diego, CA) or 
mu-p75-saporin (0.4µg/ventricle; Advanced Targeting Systems) for the hippocampal 
degeneration model or a novel neurotoxin, UII-SAP (0.5µg/ventricle; Advanced Targeting 
Systems) or control toxin, unconjugated SAP (0.5µg/ventricle; Advanced Targeting 
Systems) diluted in sterile PBS solution for the neurotrophin withdrawal model. The 
infusions were conducted over 2 mins, with a post injection wait of 5 mins to allow diffusion 
of the toxin into the ventricles and a slow retraction of the needle over 2 mins. These 
injections were performed using a 30-gauge needle attached to a 0.5µl Hamilton syringe.  
 
For medial septum (MS) injections, a 33-guage needle (C315I/SP; Plastics1) was attached 
to tubing, which was connected to a 5µl Hamilton syringe on an infusion pump (11plus 
ADV PUMP; Harvard Apparatus). The needle was lowered into the medial septum at the 
following co-ordinates; A-P; +1.0, M-L; 0.0mm, D-V; -4.4mm from Bregma. The infusion 
	   26	  
was performed over 2 mins, after which the needle was left in place for 8 minutes, 
retracted 0.5mm and left for additional 2 mins and slowly withdrawn out.  
 
After the surgery, the mice were injected subcutaneously with the analgesic torbogesic 
(1.3mg/kg) and the antibiotic Baytril (0.43mg/kg). For post surgery care, mice were given 
another analgesic and antibiotic injection the next day, were weighed daily to record any 
weight loss and were given mashed food for 3 days post surgery.  
2.6.	  Behavioural	  Experiments	  
2.6.1.	  Passive	  place	  avoidance	  
Mice were subjected to a passive place avoidance behavioural paradigm to test their basal 
forebrain dependent idiothetic navigation (self-motion kinaesthetic cues). In this navigation 
task all external cues were eliminated to minimize allothetic navigation (spatial 
relationships to cues). The apparatus used included a grey opaque arena (80cm diameter, 
20cm high) placed on a square grid of parallel metal rods (4mm diameter, 5mm apart) on a 
stainless steel table 1 meter above the floor. This set up was enclosed in a 2 metre by 2-
metre space with grey sound attenuating curtains. The light and sound in the room was 
maintained and the equipment was cleaned with 70% ethanol before the mice entered the 
arena.  
 
Mice were placed in the arena directly opposite to the shock zone and were returned to 
their cage following the trials. On day one, all mice underwent a habituation session where 
they were allowed to explore the arena freely for 5 minutes without receiving any shocks. 
After one hour mice went through the training phase of the test where they had to learn to 
avoid a set 60o shock zone. If the mice entered the shock zone during training, they 
received a 0.4mV foot-shock for 0.5 second with an interval of 1 second between shocks 
and an entrance delay of 500ms. To determine their memory of the shock zone, the mice 
we placed in the arena 24hours later and were allowed to explore without shocks being 
applied. Mice were tested for 5 minutes for their ability to avoid the shock zone.  
 
In order to analyse the performance, the following parameters were measured: the 
distance travelled by the mice, the number of entries into the shock zone, the number of 
shocks received and the homing score (the area the mouse spent the most time in away 
from the shock zone). The homing score was based on the spread of the area and the 
fraction of time the mouse spent opposite to the shock zone.  
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2.6.2.	  RotaRod	  
Accelerating RotaRod (UGO Basile Biological Research) was used to the test the motor 
integrity of mice after surgery for Aim 2b . Mice were positioned on the rotating arm of the 
RotaRod travelling at 2rpm. The acceleration was set to 0.4rpm/sec up to a maximum of 
20rpm. Measurements were made over 180 seconds and the falls prior to 180 seconds 
were recorded. 
2.7.	  Histological	  Analysis	  	  
2.7.1.	  Perfusions	  
Following the delivery of biotin-TAT-c29, mice that were to be used for histological analysis 
of biotin-TAT-c29 distribution were deeply anaesthetized with a 100mg/kg sodium 
pentobarbital intraperitoneal injection at each of the time points stated above. The mice 
were then transcardially perfused with 25mls of Phosphate Buffer Saline (PBS 1X, pH 7.4) 
followed by 50mls of 4% paraformaldehyde in 0.1M phosphate buffer (PB), pH 7.4. The 
brain and the spinal cord were dissected out and post fixed in 4% PFA. Brains were post 
fixed overnight at 4oC while the spinal cord was post fixed for 45 mins at room 
temperature. Post fixation, the brain and spinal cord were thoroughly washed in PBS 
before placing them in 20% sucrose solution overnight for cryoprotection. Brains were 
sectioned using a sliding microtome (SM2000r; Leica, Sydney, Australia) at 40µm coronal 
thickness in three serially adjacent sets. These sections were stored in 0.1% sodium azide 
in 0.1M PBS. Spinal cords on the other hand were embedded in OCT (Optimal Cutting 
Temperature embedding medium) and were frozen using dry ice and cold ethanol. These 
specimens were stored at -80oC until they were ready to be sectioned coronally on the 
cryostat at 20µm thickness into five series. 
 
2.6.2.	  Peroxidase	  Immunohistochemistry	  
The peroxidase immunohistochemistry experiments were performed by repeatedly 
washing the sections in 0.1M PB, followed by one 30 minute 50% ethanol and a 30-minute 
50% ethanol and 3% hydrogen peroxide (H2O2) wash. The sections were blocked in 5% 
normal horse serum in 0.1M PB for 30 minutes before they were incubated with the 
primary antibodies (Refer to Table 2.1) for 48 hours at 4oC diluted in 0.1M PB with 2% 
horse serum and 0.1% Triton X-100. The sections were then washed 3 times with 0.1M PB 
and probed with secondary antibody at room temperature overnight (either with the 
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biotinylated donkey anti-rabbit, biotinylated donkey anti-mouse or biotinylated donkey anti-
goat at 1:1000; Jackson Immunoresearch Laboratories, West Grove, PA) diluted in 0.1M 
PB with 0.1% Triton X-100. After washing excess secondary with 0.1M PB, next day the 
sections were then incubated for 2 hours at room temperature in ABC reagent (Vector Elite 
kit: 6 µl/ml avidin and 6 µl/ml biotin; Vector Laboratories, Burlingame, CA). To achieve the 
dark immunoreactivity, a nickel intensified diaminobenzidine reaction was performed 
whereby sections were first incubated in 0.1M sodium acetate buffer for 20 minutes 
followed by a 15 minute incubation in DAB solution (comprising of 0.1M acetate buffer, 2% 
nickel sulphate, 0.2% D glucose, 0.04% ammonium chloride and 0.025% 3,3-
diaminobenzidine). Adding glucose oxidase enzyme (0.2µl/ml) then started the peroxidase 
reaction, which was stopped with 0.1M acetate buffer solution (pH 6.0). The sections were 
repeatedly washed in 0.1M PB before mounting they were mounted onto chrome-allum 
treated slides. Slides were then dehydrated in 100% ethanol twice (3 minutes/ wash), 
cleared twice in Xylene and coverslipped with DePeX (Distrene-80/plasticizer/xylene; 
Crown Scientific, Sydney, Australia). The slides were then scanned on the Zeiss Axio 
Imager Z1 and analysed using the Imaris software (v7.5, Bitplane). 
2.7.3.	  Thioflavin	  	  
Thioflavin S stain was used for the detection of amyloid beta plaques for Aim 2c. To 
perform this staining, 40 um hippocampal slices were first mounted onto slides in order 
from anterior to posterior. The slides were cleaned twice in dH2O (5mins/wash), then 
placed in filtered 0.5% Thioflavin S solution made in dH2O for 5 mins and then washed in 
70% ethanol for 5 minutes. The slides were then incubated with Dapi nuclear stain 
(1:5000) made in 0.1%Triton-X for 4hours at room temperature. The slides were washed in 
PBS 3 times then rinsed twice in dh20 and coverslipped using DAKO (S3023) aqueous 
mounting medium. 
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Primary Antibodies  Bright-field 
IHC 
Western 
Blotting 
Company 
Goat anti ChAT (Acetylcholine 
Transferase)  
1:1000 - Jackson Laboratories 
Mouse anti Parvalbumin  1:1000 - Millipore 
Rabbit anti 9992  (Intracellular 
p75NTR)  
1:1000 1:1000 Huber & Chao, 1998 
Rabbit anti Phospho-p44/42 MAPK 
(Erk1/2)  
1:700 1:1000 Cell Signalling – 
9101S 
Mouse anti GFAP (Anti-Glial Fibrillary 
Acidic Protein) 
1:50000 - Dako 
Anti-Human p75NTR pAb - 1:1000 Promega 
Anti-p75NTR (Neurotrophin Receptor) 
Antibody 
- 1:2000 Millipore – 07476 
 
Table	  2.1	  –	  List	  of	  primary	  antibodies	  used	  for	  immunohistochemistry	  and	  western	  blotting	  
2.8.	  Cell	  Quantification	  and	  Imaging	  
Basal forebrain ChAT cell positive counts were performed for Aims 1a, 1b, 1c and 3 and 
Mesopontine nuclei ChAT cell counts were performed for Aim 1b. All counts were 
manually quantified on 20x magnification images whilst being blind to treatment, age or 
genotype. Bilateral counts of ChAT immunoreactive cells were conducted through the 
rostro-caudal extent of 120µm apart sections.  
 
For the basal forebrain three different nuclei were identified and counted: medial septum 
(MS), vertical diagonal band (VDB) and horizontal diagonal band (HDB). In the 
mesopontine tegmentum two nuclei were quantified: laterodorsal tegmentum (LDT) and 
pedunculopontine tegmentum (PPT) All nuclei were identified and defined according to the 
Mouse Brain in Stereotaxic Coordinates Atlas (Franklin and Paxinos, 2007).  
 
Peroxidase stained sections were imaged using a Metasystems bright field slide scanner 
(Zeiss Azio Imager Z2 microscope). The slides were first prescanned at 5x magnification 
and the final images were obtained in three Z-stacks using a 20x magnification objective 
lens. Images were processes and analysed using Imaris 7.5 software (Bitplane Scientific 
Software). The positively stained cells were counted using the “Spots” application on 
Imaris.  
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Counts for the Thioflavin stained hippocampal sections were performed manually using an 
Upright Zeiss Axio Imager Z1 under a 40x objective lens. Green fluorescence indicating 
the Aβ plaques were counted along the rostral to caudal axis bilaterally along the 
hippocampus in 240um apart 40um thick sections. 
2.9.	  Statistical	  Analysis	  
Quantitative data was analysed using GraphPad Prism 5 for Mac OS X software 
(GraphPad Software, Inc). To analyse the effect of surgery/treatments on cell counts and 
behaviour, a one-way ANOVA was performed for the comparison of the mean cell count 
(±SEM) between different groups.  
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Chapter	  3	  -­‐	  Models	  of	  degeneration	  to	  test	  the	  efficacy	  of	  c29	  
3.1.	  Introduction	  
Based on in vitro experiments which demonstrate that c29 can inhibit cell death (Coulson 
et al., 2000a, Matusica et al., 2013). The Coulson group next wanted to determine whether 
c29 fragment of the p75NTR receptor could promote neuronal rescue in context of 
neurotrophin dependent neurodegeneration.  
 
In particular, I was interested in testing the efficacy of biotin-TAT-c29 in an AD model, 
where as others in the laboratory aimed to test biotin-TAT-c29 in other degenerative 
models that p75NTR-death signalling had been strongly implicated including motor neuron 
disease. As highlighted in section 1.4, classic AD mouse models do not undergo frank cBF 
neuron loss. The aim of experiments describe in this Chapter was to investigate other 
mouse models for their ability to exhibit neurotrophin-mediated degeneration. The three 
models chosen for investigation were: 
(i) the senescence accelerated model of basal forebrain degeneration,  
(ii) a neurotrophin withdrawal model of cholinergic basal forebrain degeneration 
(iii) Aβ hippocampal degeneration model 	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3.2.	  Senescence	  accelerated	  model	  of	  basal	  forebrain	  degeneration	  
3.2.1.	  Background	  
The senescence accelerated mouse (SAM) model is a model of accelerated aging 
established through phenotypic selection of mice from an inbred genetic pool of the AKR/J 
strain of mice (Butterfield and Poon, 2005). This resulted in SAM model mice which 
include nine senescence-accelerated mouse prone (SAMP) sub-strains and three major 
senescence-accelerated mouse resistant (SAMR) sub-strains, each of which exhibit 
specific aging related phenotypes (Takeda et al., 1981).  
 
Our interest focussed on the SAMP8 strain which displays a number of features typical of 
early pathogenesis of AD such as learning and memory impairment, increased oxidative 
stress, cholinergic deficits, anxiety, age dependent Aβ deposition, and changes in 
membrane lipids and circadian rhythm disturbances (Flood and Morley, 1993, Butterfield et 
al., 1997, Miyamoto, 1997). Due to these features, the use of SAMP8 mice in gerontology 
research, especially dementia, has increased. 
 
The mechanism of age related cognitive decline in these mice is still not entirely clear but 
studies have attributed it to genetic alterations encoding proteins related to 
neuroprotection, signal transduction, protein folding, protein degradation, immune 
response and reactive oxygen species production (Butterfield and Poon, 2005). Evidence 
suggests oxidative stress and abnormal APP and Aβ metabolism to be the primary cause 
of learning and memory deficits in SAMP8 mice. It has been reported that increased Aβ 
accumulation occurs in the hippocampus of these mice and is associated with increasing 
age (Del Valle et al., 2010, Manich et al., 2011). In addition, administration of antisense 
oligonucleotides directed against APP to aged SAMP8 mice resulted in an improvement in 
cognition in association with a reduction in Aβ-induced oxidative stress (Kumar et al., 
2000, Poon et al., 2004). The age related abnormalities in this model together with the link 
between Aβ accumulation and cognitive deficits indicate that the SAMP8 mouse model 
could be a useful animal model of Alzheimer’s disease. 
 
In particular, our interest in the SAMP8 being a model of neurodegeneration to test the 
efficacy of biotin-TAT-c29 peptide arose from data showing a cholinergic deficit in the 
basal forebrain region of the SAMP8 mice at 6-8 months of age (Strong et al., 2003, 
Matsui et al., 2009). This supported the cholinergic hypothesis of AD, which proposes that 
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the cognitive decline noted in aging and AD brains is due to the dysfunction of 
acetylcholine-containing neurons of the forebrain.  
 
However, although Matsui et al, showed an apparent rescue of the basal forebrain 
neurons with magnolol and honokiol treatment, the results regarding survival of cBF 
neurons were difficult to interpret. SAMP8 mice were treated at 2 months of age for 14 
days. Mice were analysed at 6 months of age and displayed an increased number of 
cholinergic neurons at 6 months compared to untreated 2 month old SAMP8 mice (Matsui 
et al., 2009). The number of ChAT-positive cells in treated SAMP8 mice were also 
comparable to that of the SAMR1 control strain. However, these results suggest that rather 
than rescue of cholinergic neuron death, the expression of ChAT per cell was altered, 
and/or that there was a strain difference in either ChAT expression or absolute cholinergic 
neuron number between the two strains.  
 
My first aim was therefore to determine if cholinergic neurons degenerated in SAMP8 mice 
and the period of time during which this occurred. Once defined, animals could be treated 
over that time period with biotinylated c29 peptide to determine whether the treatment 
inhibited the degeneration. 
3.2.2.	  Results	  
Based on the report that that the basal forebrain of SAMP8 mice contain 50% fewer ChAT 
neurons at 6-8 months of age when compared to the SAMR1 control mice, the strain which 
is commonly used as controls for SAMP8 mice (Strong et al., 2003), we analysed mice at 
3, 4, and 6 months of age. Mice were perfused and processed for histological analysis. 
Counts of ChAT –positive neurons in the basal forebrain were performed for animals at 
each time point. As our subsequent treatment design was to compare c29-treated and 
control-treated SAMP8 mice over a time period, we did not use the SAMR1 for comparison 
but compared the results longitudinally. Our positive control for the immunostaining was 
wildtype C57bl6 animals. 
 
The analysis revealed that SAMP8 mice had significantly fewer ChAT-positive basal 
forebrain neurons compared to C57Bl6 animals but that there was no significant age-
related decline in ChAT cell number between 3 and 6 months in the SAMP8 animals 
(Figure 3.1). 
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Figure	  3.1-­‐	  Number	  of	  ChAT	  neurons	  in	  the	  basal	  forebrain	  region	  of	  SAMP8	  mice	  at	  3,	  4	  and	  6	  months	  of	  
age	  
Photomicrographs show ChAT-positive neurons in the basal forebrain of SAMP8 mice of ages 3, 4 
and 6 months compared to a c57/Bl6 WT control. The ChAT-positive neurons in the basal forebrain 
were counted as shown in the graph. The SAMP8 mice had significantly lower ChAT counts than 
the controls (p=0.01), however there was no significant difference between the ChAT counts of 
different ages of SAMP8 mice (p=0.58, n=2 per group).  
 
Based on these preliminary investigations, SAMP8 mice did not display an age dependent 
loss of ChAT-positive neurons in the basal forebrain between 3 and 6 months of age 
(figure 3.1). While SAMP8 mice have ~50% fewer cholinergic basal forebrain neurons 
compared to C57Bl6 animals, this deficit did not occur in an age dependent fashion, at 
least post adulthood (figure 3.1).  
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In support of this conclusion, immunohistochemistry analysis had also revealed a 
significant difference in the brain morphology of these mice compared to controls. Firstly, 
the size of the lateral ventricles were much smaller in the SAMP8 mice. Secondly, despite 
being stained in the same batches as the C57Bl6 sections, the intensity of the ChAT 
immunostaining was fainter compared to controls with less positive cells not only in the 
basal forebrain but also in the striatum (which contains cholinergic interneurons). 
 
 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  3.2	  -­‐	  The	  brain	  morphology	  of	  SAMP8	  mice	  is	  different	  when	  compared	  to	  wild	  type	  control	  
2x photomicrographs shows coronal section at the level of the basal forebrain of a 3 month old 
control and SAMP8 mouse stained with the ChAT antibody (n=2, scale bars 1mm) 
3.2.3.	  Discussion	  
The primary goal of these experiments was to characterise the time course of cholinergic 
degeneration in the SAMP8 mouse model to determine its suitability to be used as a model 
to test the efficacy of the c29 peptide in preventing cholinergic basal forebrain neuronal 
degeneration. 
 
We did not observe a reduction in the basal forebrain number with age between 3 and 6 
months of age of SAMP8 mice. This is in agreement with the Matsui et al study where 
there was no significant reduction in ChAT-positive neuron number between untreated 
mice aged 2 months and 6 months of age. (Matsui et al., 2009). However, a previous 
publication reported an age related change in the ChAT activity between SAMP8 mice age 
4 months and 8 months (Strong et al., 2003). This difference could be due to the fact that 
this paper used ChAT enzymatic activity as a measure of function, as opposed to counting 
the number of ChAT positive neurons in the basal forebrain. This also suggests the result 
Wild type control SAMP8 
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of Matsui et al., may be due to a decline in cholinergic function rather than neuron number 
per se.  
 
Thus far, no publication has reported ChAT–positive neuron number levels at 1-2 months 
of age in these mice. However, we speculate that the reduced cholinergic cell number is 
due to altered development. It is possible that SAMP8 mice have reduced ChAT 
expression from birth with a further decrease seen in the level of ChAT activity between 4-
8 months.  
 
As our primary outcome measure with c29 treatment was to be neuronal survival, our 
choice of counting ChAT positive neurons through immunohistochemistry was more 
relevant to our goal. Similarly, while we could analyse mice younger than 3 months, any 
change in ChAT neuron number would not be old-age dependent and therefore this would 
not be the ideal model to test the efficacy of biotinylated c29 peptide.  Although this mouse 
model is not sutiable for the purpose of our study, that the SAMP8 mice apparently have 
age-related reduction in ChAT activity could make these mice an excellent model for 
studying cognitive decline and aging. 
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3.3.	  	  Neurotrophin	  withdrawal	  model	  of	  cholinergic	  basal	  forebrain	  degeneration	  	  
3.3.1.	  Background	  	  
The cBF contains the largest population of cholinergic neurons in the brain and is 
implicated in cortical activation, attention and memory. Degeneration of basal forebrain 
neurons also occurs in neurological disorders including Alzheimer’s disease, Parkinson’s 
disease and schizophrenia (Zabroszky et al, 2012). The cholinergic neurons of the basal 
forebrain project to various areas of the brain: including the cortex, the hippocampus and 
the amygdala as illustrated in the schematic below (Figure 3.3).	  
	  
	  
Figure	  3.3.	  -­‐	  	  Schematic	  shows	  the	  major	  cholinergic	  populations	  and	  their	  projections	  in	  the	  brain	  
(Woolf,	  1991)	  	  
The largest population of cholinergic neurons in the brain is in the basal forebrain (red) which 
comprises of the Medial Septum (MS), Vertical Diagonal Band (VDB) and Horizontal Diagonal 
Band (HDB). The second largest population is in the mesopontine tegmentum (MPT) area located 
in the peduncular pontine (blue) which comprises of the laterodorsal tegmentum (LDT) and the 
pedunculopontine tegmentum (PPT). Lastly, the third cholinergic nuclei are the interneurons of the 
septum.  
 
Our main interest for this aim was to investigate the MPT which comprises of two nuclei: 
the laterodorsal tegmentum (LDT) and the pedunculopontine tegmentum (PPT). MPT 
neurons innervate the basal forebrain and other important thalamocortical regions known 
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to regulate REM sleep (Woolf and Butcher, 1986, Woolf et al., 1990). It has been 
previously postulated that REM sleep disruptions can exacerbate cognitive decline in AD. 	  
A project was initiated in the Coulson and Bellingham labs to investigate the link between 
MPT and cBF dysfunction and disrupted sleep in AD. Preliminary data from that study 
showed a surprising link between ablation of the mesopontine tegmentum (MPT) 
cholinergic neurons in the midbrain and a loss of the cBF neurons in the medial septum. 
We hypothesised it was due to a dependence of cBF neuron on supply of NGF from the 
MPT cholinergic innervation for their survival. It is well established that cBF neuron is 
dependent upon NGF/TrkA signalling for survival and reduced levels of NGF and or TrkA 
are associated with AD (Mufson et al., 1997, Capsoni et al., 2000). Furthermore cBFN 
degenerate when NGF supply is eliminated (Mufson et al., 1997, Capsoni et al., 2000, 
Fahnestock et al., 2001). Recent evidence suggests that the LDT cholinergic neurons of 
the MPT produce NGF, raising the possibility of the dependence of medial septum 
cholinergic population on MPT derived NGF for survival rather than cortical derived NGF 
(Ramos et al., 2011).  
 
For this aim of my project we wanted to confirm that loss of LDT neurons resulted in 
degeneration of cBF neurons. To lesion the LDT neurons, we used a toxin in which 
saporin is conjugated to an Urotensin II receptor peptide. This peptide can be specifically 
taken up by and kill only neurons expressing Urotensin II receptor-expressing neurons 
(Huitron-Resendiz et al., 2005, Jegou et al., 2006). The specificity of the Urotensin-II 
receptor to the MPT cholinergic neurons has previously been demonstrated in rats; using 
in situ hybridisation, Urotensin-II receptor mRNA was found to be expressed only in MPT 
region and co-localised with ChAT (Clark et al., 2001). Binding sites for the Urotensin II 
peptide throughout the brain have also been analysed revealing that the highest level of 
UII-receptor was the cholinergic mesopontine area (Clark et al., 2001). 
 
The experiments for this aim were designed on the basis of preliminary data obtained from 
an honours student (Nicola Marks, Honours thesis, 2012) who reported a significant 37% 
(n=3; p>0.05) reduction in the number of MS cBF neurons following MPT UII-Saporin 
injection coincident with a 67% MPT cholinergic neuron lesion (p>0.001 n=3). 
	   39	  
3.3.2.	  Results	  
In order to replicate the previous findings and therefore validate the use of this toxin for 
specifically lesioning MPT cholinergic neurons, the paradigm was repeated using a large 
cohort of c57/Bl6 wild type mice (12 per group). Mice were injected with either IgG-Saporin 
control or UII-saporin target toxin. Three weeks after surgery, mice were sacrificed and 
ChAT counts of the LDT nuclei of MPT and the MS nuclei of the histological sections 
containing the basal forebrain were preformed. UII-saporin toxin injected animals showed 
a 44% decrease in the cholinergic neuron number in LDT and a significant 26% decrease 
in the cholinergic neurons of MS region in the basal forebrain (Figure 3.4.). 
 
	  
Figure	  3.4.	  -­‐	  Loss	  of	  ChAT	  neurons	  with	  UII-­‐saporin	  toxin	  in	  the	  LDT	  and	  MS	  
ChAT-positive neurons counts in the laterodorsal tegmentum nuclei of the mesopontine 
tegmentum shows a significant 44% reduction in ChAT neurons with the UII-saporin toxin (n=12, 
p<0.0001). ChAT positive neuron count in the medial spetum of the basal forebrain also revealed a 
significant 26% reduction in the ChAT counts in the UII-sap injected mice (n=12 per group, 
p<0.0351).  
 
To determine whether the loss of neurons in the basal forebrain was cholinergic specific, 
the number of parvalbumin positive neurons were assessed in the MS, VDB and HDB 
nuclei of the basal forebrain. No change in GABAergic neuron population was observed 
(figure 3.5.) suggesting that the toxin selectively ablated the cholinergic neurons. 
 
 
LDT Lesion
Co
ntr
ol
Le
sio
n
0
200
400
600
800
 
C
hA
T 
co
un
t (
no
 o
f c
el
ls
)
***	  
Co
ntr
ol
Le
sio
n
0
100
200
300
400
500
MS Lesion
 
Ch
AT
 co
un
t (
no
 o
f c
el
ls)
*	  
	   40	  
 
Figure	  3.5.	  -­‐	  No	  change	  of	  Parvalbumin	  positive	  neurons	  with	  UII-­‐saporin	  toxin	  in	  the	  basal	  forebrain	  
Quantification of the parvablumin stained GABAergic cells in the basal forebrain of the mice 
injected with the UII-saporin toxin and the control IgG-saporin toxin did not show a significant 
difference in the number of cells in each group (n=2 per group). 
 
Prior to sacrifice, these mice also underwent behavioural testing to determine the effect of 
the lesion on their spatial navigation abilities. Firstly, the mice were tested using the 
RotaRod, a method of measuring locomotion and coordination, to examine any deficits in 
motor function as a result of death of cholinergic neurons in the pontine area. No 
difference between UII-saporin treated and control IgG-saporin treated animals was 
recorded with all animals remaining on the apparatus for the 3-minute measurement 
period (Figure 3.6). This result indicated that mice that underwent surgery with the UII-
saporin toxin had no substantive motor deficits. 
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Figure	  3.6.	  -­‐	  UII-­‐saporin	  and	  control	  injected	  mice	  performance	  on	  the	  RotaRod	  
UII-saporin lesion did not affect the motor performance of mice on the RotaRod task. Both lesioned 
and control mice performed similarly on the task (n=8 per group, no significant difference in 
means).  
 
Secondly, mice were subjected to a passive place-avoidance behaviour paradigm which 
has been validated in the Coulson lab to test for basal forebrain dependent spatial 
navigation abilities (Hamlin et al, 2013). The performance of the mice in the paradigm was 
measured in two ways: the number of shocks mice received after training on the paradigm 
and the homing score for each of the mice groups (Figure 3.7). 
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Figure	  3.7.	  -­‐	  UII-­‐saporin	  and	  control	  injected	  mice	  performance	  on	  the	  passive	  place	  avoidance	  paradigm	  
The data suggested a trend towards impairment in basal forebrain dependent spatial navigation in 
mice that were lesioned using the UII-saporin toxin (n=8) when compared to the control toxin (n=7) 
(p=0.1625). Two measures used to analyse the task include: a) No of shocks received and b) the 
homing angle which is the area measured in degrees that the animal defines as home, away from 
the shock zone.  
 
Figure 3.7a indicated that there was a trend towards mice lesioned with UII-saporin toxin 
receiving a greater number of shocks with a significant variability in the number of shocks 
received by each mouse. This difference in average shock number did not however reach 
significance. Figure 3.7b indicates the homing angle where a smaller homing score 
represents the ability of mice to spatially navigate and define a small area as home. Again 
there was no statistically significant difference, however, the data suggests that the control 
IgG injected animals defined a smaller area as home compared to UII-sap injected mice 
which had larger homing scores. These results are consistent with our previous study that 
loss of cholinergic basal forebrain neurons correlates with impairment in the place 
avoidance task resulting in greater shock number and larger homing scores (Hamlin et al, 
2013). 
3.3.3.	  Discussion	  
The primary focus of this aim was to validate a model of neurotrophin dependent 
degeneration which could be rescued using the biotin-TAT-c29 peptide. The approach we 
took was based on a surprising link found in the lab. In experiments which were aimed at 
investigating the role of mesopontine tegmentum cholinergic neurons in REM sleep and 
obstructive sleep apnoea, it was found that ablation of the mesopontine tegmentum 
cholinergic neurons resulted in the death of medial septum cholinergic neurons of the 
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basal forebrain. For the purpose of my project, I further examined this association between 
the two major cholinergic populations of the brain. 
 
The results indicated specific and significant death of medial septum cholinergic neurons 
in the basal forebrain as a consequence of a lesion in the cholinergic neurons of the 
laterodorsal tegmentum nuclei of the mesopontine tegmentum area. This loss in the basal 
forebrain was specific to the cholinergic neurons, as the GABAergic population was not 
affected. The behavioural data did not reveal any motor deficits in the lesioned mice 
indicating locomotion controlled by the pontine area was unaffected. By contrast the trend 
towards spatial navigation impairment suggesting the lesion can result in impairment of a 
basal forebrain-dependent behaviour task. 
 
This association between LDT and MS has previously been seen by Woolf et al, 1990 
where electrical stimulation of MPT resulted in altered density of ChAT staining within the 
basal forebrain (Woolf et al., 1990). The LDT neuron cholinergic axonal projections 
comprise of the vast majority of cholinergic innervations from the MPT to the basal 
forebrain (Woolf and Butcher, 1986, Woolf et al., 1986) and so it is not surprising that loss 
of cholinergic neurons in MPT region can trigger the loss of neurons in the basal forebrain.  
 
The basal forebrain is dependent on NGF/TrkA survival signalling throughout life and the 
imbalance in this signalling is associated with Alzheimer’s disease (Mufson et al., 1997, 
Capsoni et al., 2000). Basal forebrain cholinergic neurons have been suggested to derive 
their survival promoting NGF from targets such as the hippocampus and the cortex to 
where its projections extend (Gu et al., 1998). Sufficient NGF from these targets is 
essential for the regulation of basal forebrain plasticity. The loss of cortical NGF reduces 
the innervation of basal forebrain neurons to the cortex and results in memory impairment. 
By contrast, enhancing the expression of NGF either exogenously or through repetitive 
learning tasks increases basal forebrain cholinergic innervation to activated cortical 
neurons and augments synaptic function and memory (Brooks et al., 2000a, Prakash et 
al., 2004). Nonetheless, supply of NGF to the basal forebrain cell bodies rather than from 
the cortex is most potent at keeping basal forebrain neurons alive in the absence of NGF 
(Hu et al, 1997). 
 
We therefore speculate the reason for the degeneration in the medial septum to be as a 
result of depletion of NGF produced by the LDT neurons. Since the LDT neurons, which 
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project to the MS produce NGF (Ramos et al., 2011) its possible that the basal forebrain 
cholinergic neurons die due sudden loss of NGF positive innervations from the MPT 
neurons.  
 
Thus far our results indicate that the death of the medial septum neurons is a 
consequence of the death of LDT neurons. This is supported by literature, as there is no 
expression of UII-receptor in the basal forebrain (Clark et al., 2001, Jegou et al., 2006). 
While there is a possibility that the death could be non-specific due to the proximity of 
basal forebrain to the site of injection (lateral ventricles) we think its unlikely as no change 
was seen in the parvalbumin GABAergic population, suggesting that the death is ChAT 
specific. However, in order to completely eliminate the possibility of BFCN death being 
non-specific, injection of the toxin directly into the MPT region should also be performed. 
This was attempted as part of this project, however due to the location of the pontine 
nuclei in the brain, significant optimisation was required to determine the optimal 
stereotactic injection route. 
 
Future experiments will focus on examining if the death seen in the medial septum is due 
to loss of trophic support or through another phenomenon occurring as a result of surgery. 
A possible experiment to examine this would be repeating the surgeries using the UII-
saporin toxin in mice overexpressing NGF. Currently, we have a conditional NGF 
overexpression mouse which uses the cre-lox system. Crossing the NGF mouse to a 
ChAT-cre mouse will result in overexpression of NGF in all ChAT neurons including the 
neurons of the basal forebrain and the remaining neurons of the mesopontine tegmentum. 
If the death seen in the basal forebrain in this model is due a loss of trophic support then in 
these mice a rescue of basal forebrain cholinergic neurons should be expected.  
 
Another possible way of rescuing the death of basal forebrain neurons is the use of biotin-
TAT-c29 peptide. Based on our hypothesis of biotin-TAT-c29 functional mechanism, we 
believe that in this model, biotin-TAT-c29 will be able to interact with TrkA in the basal 
forebrain to enhance its activity and compensate for the loss of NGF from the MPT-
neurons. 
 
Currently, the behavioural data from this model is non-conclusive despite the presence of 
a significant basal forebrain lesion. While there was a trend towards basal forebrain 
impairment using the passive place avoidance task, the data failed to reach significance. 
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The task should be repeated on a larger cohort of mice. In addition, other navigation tasks 
such as the Morris water maze could be performed. The medial septum area of the basal 
forebrain predominantly projects to the hippocampus which is responsible for spatial 
navigation. Therefore, testing these mice on the morris water maze will examine changes 
in hippocampal function as a consequence of basal forebrain loss (Catts et al., 2008). 	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3.4.	  	  Aβ	  hippocampal	  degeneration	  model	  
3.4.1.	  Background	  
At a neuropathological level, amyloid plaques, neurofibrillary tangles, progressive synaptic 
and neuronal loss are the key hallmark features of Alzheimer’s disease. Although 
overexpression and deposition of Aβ appears to be the primary cause of the disease, the 
basal forebrain cholinergic neuron’s vulnerability to the toxicity associated with the disease 
is not adequately explained. Our lab has recently established a significant correlation 
between the extent of basal forebrain atrophy and Aβ load in humans as measured by 
magnetic resonance imaging and a positron emission topography ligand for Aβ known as 
PiB (Kerbler et al., 2014, submitted). As most APP transgenic animal models fail to show a 
loss in cholinergic neurons we aimed to establish a ‘sporadic’ model of AD.  
 
The idea was to establish a causal link between the amyloid accumulation and cholinergic 
degeneration in AD, specifically to examine if disruptions to normal cholinergic basal 
forebrain activity would result in the production and deposition of Aβ in the hippocampus. 
We hypothesised an increase in Aβ plaque production and subsequent hippocampal 
degeneration would occur following cholinergic basal forebrain neuron lesion.  Because 
mouse Aβ is a different less toxic sequence to that of humans, we used mice susceptible 
to human Aβ production, the APP/PS1 strain. 
 
This hypothesis was based on a number of previous studies. AD11 mice have reduced 
endogenous NGF levels due to transgenic expression of an NGF antibody. These animals 
not only show cholinergic basal forebrain neuron, but also an accumulation of Aβ granules 
derived from mouse APP (Capsoni et al., 2000, Capsoni et al., 2002). SAMP8 mice also 
display Aβ accumulation and reduced basal forebrain function which appeared to be linked 
(Del Valle et al., 2010, Manich et al., 2011). Other evidence from transgenic mice models 
that supports our hypothesis comes from a paper which looked at Aβ plaque accumulation 
in p75NTR-knock out mice. This paper found there to be a 20% increase in Aβ plaques 
deposition by 6 months of age following loss of basal forebrain expression of p75 which 
binds and can help clear Aβ (Wang et al., 2011). Increased Aβ42 in the brain also occurs 
when TrkA levels in the cholinergic basal forebrain are low (Hernandez et al., 2010). 
Together these findings argue that the disruption of cBFN activity and thereby 
neurotrophin signalling could potentially result in Aβ aggregation and deposition. 	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In order to investigate this link at a molecular level, we made use of the p75-saporin model 
of cBF death in APP/PS1 mice. The p75-saporin toxin has been previously characterised 
in wild type mice whereby intracerebroventricular (ICV) injection of p75-saporin resulted in 
a specific loss of ChAT positive neurons while preserving other cell population in the cBF 
(Moreau et al., 2008). As the basal forebrain is one of the only few areas that continues 
expressing p75NTR in the adult brain post development, we would be specifically targeting 
the cBFN neurons with this toxin. 
3.4.2.	  Results	  
Initially, the p75NTR-saporin toxin was tested for its ability to induce a lesion in the 
cholinergic basal forebrain of 8-week-old APP/PS1 mice. Two weeks post ICV injection of 
p75NTR-saporin toxin into the lateral ventricles, a significant 34% reduction in the p75NTR 
positive cholinergic neurons of the basal forebrain was noted (Figure 3.8). These mice 
were also examined for the number of Aβ plaques in the hippocampus, however in this 
age group no plaques were seen. 
 
 	  
	  
	  
	  	  	  
Figure	  3.8.	  -­‐	  Ablation	  of	  p75	  expressing	  ChAT	  neurons	  with	  p75-­‐saporin	  toxin	  in	  APP/PS1	  8	  week	  old	  
mice	  after	  2	  weeks	  
Number of ChAT-positive neurons in the basal forebrain of mice 2 weeks after bilateral injection of 
p75-saporin (n=4) or control IgG-saporin (n=3) were counted. p75-saporin resulted in a 34% loss of 
cholinergic neurons in the basal forebrain compared to the control condition (p=0.0011).  
 
To test our hypothesis of increased plaque production in the hippocampus as a result of 
basal forebrain death, further surgeries were performed on mice of different age groups – 
8 weeks, 12 weeks and 17 weeks. The 8 week old mice were housed for 2 months after 
the surgery while the 12 weeks and 17 week mice were housed for 1 month post surgery. 
At all ages there was a significant reduction in the number of p75NTR-positive cholinergic 
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neurons of the basal forebrain region. The 17-week-old mice display the biggest reduction 
of 53.5% in ChAT counts (figure 3.9). 
 
 
 
Figure	  3.9.	  -­‐	  Loss	  of	  basal	  forebrain	  ChAT	  positive	  neurons	  with	  p75-­‐saporin	  toxin	  at	  different	  ages	  	  
a) shows a 42.7% loss of cholinergic neurons in the basal forebrain of 8 week old APP/PS1 mice 2 
months after bilateral injection of p75-saporin (Statistical analysis could not be performed on this 
as there is only n=1 in the p75-saporin group). Graph b) shows a 46.5% loss of cholinergic 
neurons in the basal forebrain of 12 week old APP/PS1 mice 1 month after bilateral injection of 
p75-saporin (n=2) (p=0.0138). Graph c) shows a 53.5% loss of cholinergic neurons in the basal 
forebrain of 12 week old APP/PS1 mice 1 month after bilateral injection of p75-saporin (n=2) 
(p=0.03). 
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Mice were next examined for the number of hippocampal plaques (figure 3.10.). An 
increase in the plaque number per hippocampus section was noted for all three age 
groups. In the 17-week old mice; controls had 6±0.4 plaques/hippocampal section where 
as the p75-saporin injected animal had 10.4±0.4 plaques/hippocampal section. For the 12-
week old mice; the controls had 0.21±0.1 plaques/hippocampal section whereas the p75-
saporin injected mouse had 0.77 plaques/hippocampal section. Finally, the 8-week old 
controls had 0.28±0.1 plaques/hippocampal section compared to the p75-saporin injected 
mouse which had 2.19 plaques/hippocampal section. At all the ages, basal forebrain 
ablation using the p75NTR toxin resulted in more Aβ plaques in the hippocampus of 
APP/PS1 mice than controls (figure 3.10).  Statistical analysis was not be performed due 
to low subject numbers (n=1-2/group	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Figure	  3.10.	  -­‐	  Amyloid	  beta	  plaques	  in	  the	  hippocampus	  of	  mice	  post	  cBF	  loss	  	  
a) shows a 40x magnification of Aβ plaque stained with Thioflavin S. These plaques were counted 
in every third section through the mouse hippocampus. b) shows the quantification of the increase 
in Aβ plaque production in the hippocampus of 8, 12 and 17 weeks mice. c) shows the thioflavin S 
stained photomicrographs displaying the increase in the number of plaque production at 12 weeks 
and 17 weeks of age (20x magnification, n=2 per group, scale bars 50um). 
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3.4.3.	  Discussion	  
There is strong evidence in support of amyloid beta being the proximal cause of 
Alzheimer’s disease. However, mutations in the amyloid beta protein precursor (APP) 
gene or the enzymes that cleave the gene to produce a longer form of Aβ only account for 
less than 10% of cases of AD (Hardy et al., 1998). The overproduction of Aβ and the 
inability of the brain to degrade it is what leads to the aggregation and accumulation of 
toxic oligomeric Aβ.  The reason for all other sporadic cases of AD is yet to be elucidated. 
As well as Aβ mediated toxicity, extensive loss of acetylcholine levels and death of the 
cholinergic neurons of the basal forebrain has been noted in AD (Auld et al., 2002). The 
cholinergic neurons are responsible for cognitive abilities such as attention, learning and 
memory processes and its not surprising that their loss results in the main clinical 
hallmarks of AD.   
 
Early in the disease, degeneration takes place in two main areas: the hippocampus and 
the basal forebrain. This study was based on a link found in our lab between the load of Aβ 
in the brain as measure by PiB (Aβ binding tracer used in PET scans) and its correlation 
with the level of basal forebrain atrophy in humans. We wanted to examine if there was a 
causal link between the basal forebrain degeneration and Aβ plaque accumulation at a 
molecular level. We hypothesised that the loss of the cholinergic neurons in the basal 
forebrain precedes and results in amyloid beta plaque production in the hippocampus and 
its degeneration.  
 
Currently, there are no models of AD that rapidly develop cholinergic basal forebrain 
death. In order to test our hypothesis we developed a sporadic model of Alzheimer’s 
disease using the p75NTR toxin in order to examine the effects of basal forebrain death on 
subsequent degeneration. We were aiming to induce a threshold lesion which would have 
no or little impact on the normal cognitive functioning of these mice and therefore would 
allow us to examine the combined effect of basal forebrain loss with the APP/PS1 
genotype at a biochemical and behavioural level.  
 
Using the p75NTR- saporin toxin, approximately 50% of all basal forebrain cholinergic 
neurons and therefore the cholinergic projections to the hippocampus and the cortex were 
successfully ablated, as reported previously (Hamlin et al, 2013). According to the 
literature, APP/PS1 mice show Aβ deposition from 4 months of age (Perez et al., 2007). 
We aimed to exacerbate plaque production with the lesion in susceptible APP/PS1 mice 
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which according to the literature show Aβ deposition from 4 months of age (Perez et al., 
2007). For the mice lesioned at 8 weeks and which had 34% neuron loss at 10 weeks, no 
Aβ plaques were observed. This could be due to the 34% lesion being too minor to result 
in significant Aβ production/deposition or the two week timeline being too short to allow for 
plaque production. 
 
In our next experiment we demonstrated that a robust lesion and prolonged post surgery 
time was sufficient to aggravate Aβ plaque production in APP/PS1 mice. It was found that 
lesioning at 17 weeks, resulting in a 50% cholinergic lesion, resulted in a doubling of 
plaque number in the hippocampus. A similar trend, albeit lower total plaque number was 
also noted in mice lesioned at 12-weeks of age and lesioned at 8-week but which were 
housed for 2 months after surgery prior to analysis.  
 
While the aforementioned three studies published recently are in agreement of our model, 
their experimental design had a few discrepancies compared to ours. Laursen et al and 
Ramos-Rodriguez et al both used APP/PS1 mice at the ages of 6 and 7 months 
respectively while Härtig et al used the triple transgenic AD mice at 12 months of age. 
Laursen et al analysed the mice two months after surgeries and found there to be increase 
in Aβ plaque, decrease in ChAT activity in the hippocampus and the cortex and significant 
behavioural impairment (Laursen et al., 2013). Ramos-Rodriguez et al assessed their mice 
after one week of p75NTR-saporin surgeries and found there to be an increase in Aβ 
plaques and impairment in episodic memory (Ramos-Rodriguez et al., 2013). Finally, 
Härtig et al analysed their mice 4 months after lesion and found an increase in Aβ , tau 
and gliosis (Härtig et al., 2013).  
 
All these studies used mice of an older age group than ours. We wanted to establish the 
earliest time point before the onset of plaque accumulation where the process could be 
accelerated by the exacerbation of the cholinergic basal forebrain. We found that at ages 
as early as 12-weeks we could see a difference in plaque number. Nonetheless, the three 
studies supported our overall hypothesis and enabled us to conclude that a combination of 
partial cholinergic lesion and Aβ phenotype represents a novel model which closely 
resembles the pathophysiology seen early in AD. 
 
One main drawback of our study was the smaller subject groups. Due to the unavailability 
of APP/PS1 mice at the time of these experiments, the study lacks larger cohorts of mice 
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and therefore the appropriate behavioural data. Therefore, for the future experiments, a 
larger cohort of mice is essential to confirm the model at an early age of 12 weeks. 
However, this model provides us with an excellent degeneration model to test the efficacy 
of the c29 peptide. Future behavioural analysis should also be performed to comment on 
the memory and attention impairment in these mice and to examine if c29 treatment is 
able to prevent plaque accumulation and the subsequent behavioural degeneration.  
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Chapter	  4	  -­‐	  Optimizing	  delivery	  of	  c29	  peptide	  in	  vivo	  
	  
4.1.	  Introduction	  
To test whether biotin-TAT-c29 is efficacious in treating neurodegeneration in one or more 
of the animal models explored above, it was necessary to optimize a protocol for delivery 
and detection of c29 in vivo. The cellular target of c29 is neurons within the central 
nervous system (CNS) moreover, in the cytoplasm of those neurons; the hypothesised 
mechanism of action of c29 is its ability to bind to the intracellular cytoplasmic tail of Trk 
receptors causing an allosteric change in the receptor structure such that it binds 
neurotrophins with greater affinity and thereby initiating neurotrophic signalling cascades in 
concentrations of growth factor lower than would normally elicit such a response (Matusica 
et al., 2013).  
 
In order to aid intracellular delivery, c29 was coupled to a trans-activating transcriptional 
activator (TAT) protein transduction domain (PTD) which is a modified version of the PTD4 
sequence that has 3-4 times efficiency compared to the wild-type TAT protein sequence 
(Ho et al., 2004). Firstly this domain delivers peptides and proteins into cells (Schwarze et 
al., 1999, Coulson et al., 2000a). However and more importantly, PTDs have also been 
shown to deliver proteins and peptides to a variety of tissues including across the blood 
brain barrier (BBB), which is well known to be a major hindrance for the delivery of 
macromolecules into the brain (Schwarze et al., 1999, Gupta et al., 2005). We therefore 
tested whether c29 can be delivered into the brain following systemic application. 
4.2.	  Results	  
4.2.1.	  Intraperitoneal	  injection	  of	  biotin-­‐TAT-­‐c29	  
To establish delivery of c29 into the CNS, a biotinylated version of TAT-c29 was 
intraperitoneally injected into mice. Since TAT–coupled peptides could be immunogenic 
and excessive c29 can potentially enhance signalling resulting in adverse effects, we 
administered 2mg/kg at different time points to check if any toxicity was caused at this 
concentration. This dose is the lowest dose of a TAT-coupled peptide previously been 
reported to elicit biological outcomes in the brain following intraperitoneal delivery of 
various other TAT peptides (Schwarze et al., 1999, Asoh et al., 2002, Cao et al., 2002, 
Tao and Johns, 2008, Tao et al., 2008).  
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Mice injected with biotin-TAT-c29 were sacrificed at 1 hour, 6 hours, 24 hours and 72 
hours later following injections. Brain tissue was sectioned at 40µm slices for histological 
analysis of biotin-TAT-c29 distribution in the brain. We were particularly interested in 
examining whether biotin-TAT-c29 would be delivered to basal forebrain neurons, which 
are known to degenerate in AD and the focus of my animal models. 
 
Mice injected with 2mg/kg peptide displayed no noticeable adverse effects within the 72-
hour time frame, suggesting that the peptide is not overtly toxic at that dose. 
Immunohistochemical analysis for biotin-TAT-c29 peptide in brain sections of injected mice 
compared to naïve mice indicated the presence of biotin within basal forebrain tissue at 1 
hour, 6 hours, 24 hours and 72 hours post injection (Fig 4.1). This suggests that the 
peptide can cross the blood brain barrier within an hour of intraperitoneal injection. 
Furthermore, immunoreactivity for biotin was still above that of naïve mice at 72 hours, 
suggesting that the peptide (or its derivatives) are stable for up to 72 hours post injection.  
This was perhaps surprising given the assumption that peptides have a short biological 
half-life. 
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Basal Forebrain Neurons 
 
Un-injected negative control 
 
1 hour time point 
 
   
 
6 hours time point 
 
 
24 hours time point 
 
 
72 hours time point 
 
   
 
Figure	  4.1:	  Detection	  of	  biotin-­‐TAT-­‐c29	  in	  the	  brain	  at	  different	  time	  points	  	  
Photomicrographs of mouse brain sections at the level of the basal forebrain immunostained with 
DAB for ChAT (a) or biotin (b-f). Mice injected with the biotin-TAT-c29 peptide (c-f) display positive 
immunostaining for biotin compared to immunostaining of uninjected mouse tissue (b). All sections 
were staining and developed in parallel. Immunostanining is evident in sections from all mice 
injected with biotin-TAT-c29 regardless of analysis time post injection (n=2 animals per time point, 
scale bars – 50µm, 40X images). 
 
We next tested the amount of biotin-TAT-c29 in the brain following chronic systemic 
treatment and over an increased range of concentrations; mice were injected with one of 
three different concentrations of biotin-TAT-c29: 2mg/kg, 5mg/kg or 8mg/kg and injections 
were given every 72 hours for 6 weeks. Weight of the mice was monitored daily and mice 
were also observed for any other adverse behavioural responses. At the end of the 
injection regime, mice were sacrificed and brain tissue processed for histological 
assessment (figure 4.2.).  
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Un-injected control 
 
2mg/kg 
 
5mg/kg 
 
8mg/kg 
 
    
    
	  
Figure	  4.2:	  detection	  of	  biotin-­‐TAT-­‐c29	  in	  the	  brain	  at	  different	  concentrations	  using	  DAB	  
immunohistochemistry	  	  
Panel a and b show 2x bright field photomicrographs of the basal forebrain and the hippocampal 
area respectively. The images show the difference in staining for the biotin-TAT-c29 peptide 
between a non-injected control and mice injected with 2mg/kg, 5mg/kg and 8mg/kg c29 peptide. 
The black arrows indicate staining above background and higher than negative control (no peptide 
injected) suggesting the presence of peptide. Red arrows indicate background staining. (n=3, scale 
bars – 1mm). 
No weight loss was observed and only 1 animal (given the 8mg/kg) appeared to react to 
the injection (hunched appearance in the corner of the cage immediately post injection) on 
one occasion during the treatment course. Given the route of administration was 
intraperitoneal and no other mice were observed to have a similar response, this reaction 
was assumed to be due to the injection related rather than peptide. We concluded that 
mice could tolerate up to 8 mg/kg for at least 6 weeks administration of biotin-TAT-c29 
peptide with no obvious side effects. 
 
Histological analyses of the brain sections again revealed positive immunostaining for 
biotin compared with controls (Figure 4.2). Although there was staining observed in the 
brains of un-injected control mice (indicated by red arrows), immunoreactivity in other brain 
areas of biotin-TAT-c29-injected mice was not present in the un-injected mouse brains, 
specifically in the cortex, striatum, basal forebrain and the CA regions of the hippocampus. 
Interestingly, the immunopositive staining was predominantly associated with grey 
matter/cell bodies rather than axonal tracks. 
 
a 	  
b 
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The most likely explanation for the staining in the brains of un-injected mouse tissue is the 
presence of endogenous biotin (McKay et al., 2008). Biotin is a vitamin essential for 
metabolism and is widely distributed throughout the body, especially in the kidney, liver 
and brain (McKay et al., 2004). This presence of endogenous biotin can make avidin-biotin 
and streptavidin-biotin based immunohistochemical detection difficult to interpret. Here the 
distribution of biotin immunostaining was different in biotin-TAT-c29 treated compared to 
untreated mice, suggesting the peptide or derivative were transported to the brain. 
However, although using the avidin-biotin kit confirms presence of the biotin in the tissue, it 
does not detect the peptide itself, and it was possible that, due to degradation of the 
peptide, the detected biotin was no longer coupled to the TAT-c29 peptide. Therefore, we 
next tested whether intact peptide could be detected in cell and tissue lysates.  
 
The first method tested was to immunoprecipiate the biotinylated peptide from lysates 
using streptavidin-coated beads, followed by Western blotting of elutes with an anti-
streptavidin antibody. Lysates from PC12 cells treated with biotin-TAT-c29 and mouse 
brain lysates spiked with peptide (or naïve) were examined. Eluates were compared by 
western blot to pure peptide (Figure 4.3).  No immunopositive band of ~5kD band, 
corresponding to biotin-TAT-c29 was detected in any of the lanes including those loaded 
with different amounts of pure peptide. There were a number of higher molecular weight 
non-specific bands in pull-downs from both spiked and un-spiked lysates, but  again no 
band that corresponded to the peptide was observed in these samples. It was unlikely that 
the amount of peptide was below detection limits as 1µg of Aβ peptide – also a 40 amino 
acid peptide is detectable by western blot (Sotthibundhu, 2009). This suggested that the 
peptide was not being recognised by the anti-streptavidin antibody following western 
blotting.  	  
The results taken together indicated that the use of streptavidin-biotin detection was not 
optimal for detecting biotin-TAT-c29 by immunohistochemistry of tissue sections and was 
not possible western blotting of tissue lysates. 	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Figure	  4.3:	  Detection	  of	  biotin-­‐TAT-­‐c29	  peptide	  by	  western	  blot	  using	  a	  streptavidin	  antibody	  
Western blot probed with an anti-streptavidin 680 Alexa-conjugated antibody. Lane 1-3 were 
loaded with 100, 250 and 500ng of pure biotin-TAT-c29 peptide. Samples in lanes 4-12 are eluates 
of pull-downs using magnetic streptavidin beads. Lanes 4-6 pull-down from PC12 lysates treated 
with 10µM, 1µM or control scrambled c29 respectively. Lane 7 and 10: pull-down of un-injected 
brain lysate. Lanes 8, 9, 11 and 12 pull-down of brain lysate ‘spiked’ with 0, 100 and 500ng 
concentrations of biotin-TAT-c29 peptide, respectively. The expected biotin-TAT-c29 band is ~5kD. 	  	  
We next tested whether an antibody to the p75NTR  intracellular domain could be used to  
detect the p75NTR-derived c29 portion of the peptide. A number of polyclonal antibodies 
have been raised to the entire intracellular domain of p75NTR, and the c29 sequence is 
100% homologous across all mammalian species. These antibodies are routinely used to 
detect p75NTR and its intracellular domain fragments by western blot and 
immunocytochemistry. Three different p75NTR antibodies were evaluated for their ability to 
detect the Biotin-TAT-c29 peptide by western blot: The anti-human p75NTR antibody 
(Promega, G323A), the anti-NGF Receptor p75NTR antibody (07476, Millipore), both of 
which are commercial antibodies, and the anti-p75NTR 9992 antibody, generated by 
Moses Chao (Huber and Chao, 1995) and used routinely for immunoprecipitations and 
was a generous gift. Western blots of pure biotin-TAT-c29 peptide indicated that only 9992 
recognised the peptide (Figure 4.4). 
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Figure	  4.4.	  -­‐	  Detection	  of	  biotin-­‐TAT-­‐c29	  peptide	  by	  western	  blot	  using	  the	  p75NTR	  intracellular	  (9992)	  
antibody	  
Western blots of pure 500ng peptide probed with one of three different antibodies Only 9992 
detected a band at the expected 5kD size of the peptide.  
 
The ability of only the 9992 intracellular p75NTR antibody to detect the biotin-TAT-c29 
peptide on a western blot could be due to the ability of antibodies to bind only specific 
conformation of p75NTR/c29 peptide and/or due to the fact that each of the polyclonal 
populations of antibodies contain antibodies to different epitopes and only 9992 contains 
an antibody to the c29 region of the p75NTR intracellular domain.  
 
Next, we spiked various amounts of biotin-TAT-c29 peptide to brain lysate from naive 
animals (‘spiked’ lysate) and the lysate was then incubated with streptavidin magnetic 
beads. In this method, biotin-TAT-c29 but not endogenous full-length p75NTR should be 
retained. The pulldown eluate was then probed using the 9992 antibody following western 
blotting which revealed biotin-TAT-c29 peptide can be purified from brain lysates and 
detected by western blot (Figure 4.5). 
 
 
  
 	  
	  
	  
Figure	  4.5.	  -­‐	  varying	  concentrations	  and	  immunoprecipitation	  of	  c29	  peptide	  could	  be	  detected	  on	  a	  
western	  blot	  with	  the	  p75NTR	  intracellular	  (9992)	  antibody	  
Lane 1 shows the ladder. Lane 2-4 show biotin-TAT-c29 peptide loaded at different concentrations 
of 100ng, 250ng and 500ng. Lane 5-7 show brain lysates spiked with the c29 peptide at 0ng 
(control), 100ng and 500ng and then immunoprecipitated with streptavidin magnetic beads for 
biotin-TAT-c29.  
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No bands were seen in the control un-spiked brain lysate lane indicating that the pull-down 
was specific for the peptide. The results from this experiment also indicate that the density 
of biotin-TAT-c29 peptide detected on western blots following pull-down using streptavidin 
is reflective of the amount of peptide within the lysate. The band intensity correlates with 
the amount of peptide spiked into the lysate.  
 
Having established a method to detect the c29 portion of the peptide, we tested whether 
peptide in brain lysates from mice injected with the biotin-TAT-c29 peptide could be 
observed using this method. Whole brain lysates from mice treated for 1 hour  previously 
with 2, 5 or 8mg/kg biotin-TAT-c29, or for 1, 6, 24 or 72 hours with 2mg/kg were mixed 
with magnetic streptavidin beads to bind the biotinylated c29 peptide. The eluate from the 
beads was electrophoresed, western blotted and probed with the 9992 antibody (Figure 
4.6.).  
Figure	  4.6.	  -­‐	  Detection	  of	  c29	  peptide	  in	  brain	  lysates	  by	  western	  blotting	  with	  the	  p75NTR	  intracellular	  
(9992)	  antibody	  following	  streptavidin	  pulldown	  	  
(a) Western blot of pull-down eluates from brain lysates of mice were sacrificed at the indicated 
time point after a single i.p injection of 2mg/kg biotin-TAT-c29 peptide probed with 9992. (b) 
Western blot of pull-down eluates from brain lysates of mice treated for 6 weeks with 2, 5 or 8 
mg/kg biotin-TAT-c29 and sacrificed 1 hour after the last i.p injection, and probed with 9992.  A 
non-specific band larger than that of the positive-control peptide can be seen at ~7Kda.  In animals 
treated chronically with 5 or 8mg/kg a 4Kda band equivalent to the positive control is observed. No 
band is observed in samples from mice treated with 2mg/kg either acutely or chronically.  
 
This experiment indicates that intraperitoneal injection of 2mg/kg biotin-TAT-c29 did not 
deliver sufficient amounts of the peptide to be detected using this pull-down and western 
blot method, even when given chronically. However, this method did reveal biotin-TAT-c29 
peptide in brains of mice treated for 6 weeks with 8mg/kg and 5mg/kg. This result 
indicated biotin-TAT-c29 had the ability to cross the blood brain barrier and reach the brain 
.  
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Finally, we used the 9992 antibody to immunostain brain sections of tissue from control or 
biotin-TAT-c29 treated animals. Unfortunately, significant staining was seen with this 
antibody in un-injected animals, most likely due to endogenous p75NTR. p75NTR is 
expressed in the basal forebrain neurons and their axons which project to nearly the entire 
brain. It was therefore difficult to develop the DAB immunostaining to optimise detection of 
the peptide without overstaining the sections for p75NTR, and a definitive conclusion could 
not be made regarding the presence of biotin-TAT-c29 in the brain by this method 
 
While the adult brain expresses p75NTR in the basal forebrain throughout life, the adult 
spinal cord cells do not express p75NTR post development (Bothwell, 1995). We therefore 
examined the distribution of biotin-TAT-c29 peptide using the 9992 antibody in sections of 
spinal cord sections from the injected animals. Spinal cord sections of biotin-TAT-c29 
treated mice displayed significantly more immunoreactivity than those from control animals 
(Fig 4.7) 
 
 Un-injected control Biotin-TAT-c29 injected 
 
  
 
Figure	  4.7:	  Detection	  of	  bition-­‐TAT-­‐c29	  in	  the	  spinal	  cord	  using	  an	  intracellular	  p75NTR	  (9992)	  antibody	  	  
Bright field photomicrographs (10x) of transverse sections through the lumbar spinal cord of control 
un-injected animal and 8mg/kg biotin-TAT-c29 treated mouse sacrificed 6 weeks after 
intraperitoneal injections. The sections were immunostained using intracellular p75NTR (9992) 
antibody developed using DAB. (n=2, Scale bars: 1mm, 10x magnification). 
 
Immuno-positive anti-p75NTR staining in spinal cord sections of biotin-TAT-c29 treated 
animals was again primarily in the grey matter and also appeared to specifically label 
motor neurons within the ventral horn (as indicated by the black arrow). At the dorsal horn, 
immunostaining was also evident in the projections from the dorsal root ganglion in 
marked contrast in immunostaining in control tissue. This indicated that i.p injection of 
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biotin-TAT-c29 resulted in delivery of the peptide to cells within the spinal cord and thus 
potentially throughout the CNS. 
Although no method definitively demonstrated biotin-TAT-c29 was delivered within 
neurons of the brain, together these results make a compelling case the peptide can cross 
the blood-brain barrier following systemic. 
4.2.2.	  ERK	  activation	  –	  A	  possible	  mechanism	  for	  c29	  action?	  
One of the proposed mechanisms of biotin-TAT-c29 action is its ability to interact with and 
enhance Trk mediated survival signalling. We have previously reported the ability of c29 
peptide to promote neurite outgrowth through activation of trophic Erk1/2 and AKT 
signalling cascades mediated by Trk receptor activity (Matusica et al., 2013).   
 
PC12 neuronal cells endogenously express both TrkA and p75NTR receptor and are 
widely used to study actions of neurotrophins on their receptors.  For the purpose of our 
experiment we assessed the level of phosphorylated ERK1/2, activated by NGF treatment 
of PC12 cells alone, compared with the level in PC12 cells treated with NGF and biotin-
TAT-c29. An increase in 10ng/ml NGF mediated ERK1/2 phosphorylation to a similar 
extent as that induced by treatment with 10 fold higher NGF concentrations (100ng/ml) 
was induced by c29 treatment (figure 4.8). 	  
	  
Figure	  4.8.	  –	  Biotin-­‐TAT-­‐c29	  in	  the	  presence	  of	  limited	  NGF	  induces	  an	  enhanced	  ERK	  response	  in	  PC12	  
cells	  	  
Lane 1: ladder, lane 2-4: PC12 cells treated with either 0ng/ml, 1ng/ml or 100ng/ml NGF, lane 5-6: 
PC12 cells treated with biotin-TAT-c29 at 100uM with either 10ng/ml or 1ng/ml NGF. The western 
blot was probed with anti-phosphoERK primary antibody. NGF treatment up-regulates the level of 
pERK in a dose dependent manner. No response was noted in the absence of NGF. In the 
presence of c29 with 10ng/ml NGF, a response equivalent to 100ng NGF alone could be seen, 
suggesting that c29 increases the sensitivity of PC12 cells to NGF treatment. 
 
We therefore hypothesised that following delivery to the brain, c29 would potentiate Trk 
receptor-mediated signalling in vivo, resulting in increased (above baseline) ERK1/2 levels 
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in neurons of the brain and spinal cord. Such a result would provide indirect evidence that 
biotin-TAT-c29 was entering the neurons within the brain and spinal cord but also provide 
evidence for c29 mediating trophic effect in those neurons.  Mice were injected with 
8mg/kg peptide and scarified 7 days later and immunostained for phosphorylated ERK1/2. 	  	  	  	  	  	  	  	  	  	  
	  
	  
	  
	  
Figure	  4.9.	  -­‐	  Detection	  of	  Erk	  activation	  in	  the	  brain	  post	  c29	  peptide	  injection	  using	  a	  pERK	  antibody	  in	  
the	  brain	  	  
Bright field photomicrographs (2x, 10x) of the brain at the level of the basal forebrain were 
immunostained with anti phosphorylated-ERK (pERK) antibody to allow detection of activated 
ERK. 10x photomicrograph show activated neurons in the septal nucleus of the basal forebrain 
specifically (n=3, Scale bars: 1mm). 
 
In biotin-TAT-c29 treated mice, strong immunostaining for phosphorylated Erk1/2-
immunopositive cells were observed in the septal and cortical areas, whereas, significantly 
reduced staining was seen in these areas in the un-injected control (figure 4.9). These 
areas express the TrkB receptor and BDNF, which is released in a synaptic-activity 
dependent manner, but essentially constitutively.  
 
The extent of phosphorylated Erk1/2-immunostaining in the spinal cord of mice treated 
with biotin-TAT-c29 was similarly assessed, revealing enhanced immunostaining in the 
motor neurons of the ventral horn expressing the TrkB receptor (figure 4.10). Again the 
immunostaining was primarily within the cell bodies rather than white matter. These results 
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indicate that not only does TAT-c29 cross the blood brain barrier but that it may mediate 
enhanced trophic signalling, as occurs in vitro. 	  	  	  	  	  	  	  	  	  	  	  
	  
	  
	  
	  
Figure	  4.10.	  –	  Detection	  of	  Erk	  activation	  in	  the	  brain	  post	  c29	  peptide	  injection	  using	  a	  pERK	  antibody	  in	  
the	  spinal	  cord	  	  
Bright field photomicrographs (2x, 10x) of the brain at the level of the lumbar spinal cord were 
immunostained with anti phosphorylated-ERK (pERK) antibody to allow detection of activated 
ERK. 10x photomicrograph show activated motor neurons in the ventral horn of the lumbar spinal 
cord (n=3, Scale bars: 1mm). 
4.2.3.	  Does	  c29	  cause	  neuro-­‐inflammation?	  	  
Systemic delivery of any phamacological compound has the potential to cause side 
effects. No obvious adverse effects were observed for mice injected with the peptide 
chronically over 6 weeks, however this does not rule out toxicity as this aspect was not 
comprehensively studied herein. However, inflammation in the brain may indicate 
neurotoxicity or an detrimental immunological response caused by the peptide. We 
therefore measured the number of reactive astrocytes and microglia in the brain as an 
indicator of neuro-inflammation. We used a GFAP antibody to stain for any change in 
astrocyte number and morphology that would indicate astrocytic activation. 
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Figure	  4.11	  –	  Biotin-­‐TAT-­‐c29	  peptide	  injections	  do	  not	  cause	  inflammation	  in	  the	  brain	  
Hippocampal sections of mice injected with either 2mg/kg, 5mg/kg or 8mg/kg of peptide for 6 
weeks compared to a negative control (un-injected brain) and a positive control (an aged 
Alzheimer’s disease brain). The staining was performed using a GFAP antibody (n=2, scale bars 
1mm, magnification 10x and 20x). 
 
 
 
 
Inflammation Positive 
Control 
 
 
 
 
 
 
 
Un-injected Negative 
Control 
 
 
 
 
 
 
 
2mg/kg c29 
 
 
 
 
 
 
 
 
5mg/kg c29 
 
 
 
 
 
 
 
 
8mg/kg c29 
 
 
 
 
	   68	  
The brain of an aged Alzheimer’s disease mouse model (APP/PS1) was used as a positive 
control for neuroinflammation within in the hippocampus and cortex. In the APP/PS1 mice, 
but not GFAP–positive astrocytes were present in the cortex (red arrow) but not in the 
naïve wild-type mice or the biotin-TAT-c29 treated animals (Fig 4.10). In addition, neither 
naïve nor biotin-TAT-c29 treated animals showed increased activation of reactive 
astrocytes, indicated by upregulated GFAP intensity and larger irregular processes, in the 
hippocampus, in contrast to the immunostaining in the hippocampus of APP/PS animals 
(Fig 4.10). This indicated that biotin-TAT-c29 treatment over 6 weeks does not result in 
inflammation of the brain.	  
4.3.	  Discussion	  
The main aim of this work was to optimize delivery and detection of biotin-TAT-c29 into the 
brain and spinal cord of adult mice. Three different methods of biotin-TAT-c29 detection 
provided results following intraperitoneal injections: i) biotin detection, ii) detection using 
the 9992 p75NTR antibody and iii) staining for the effects of biotin-TAT-c29, activated 
ERK, using pERK antibody.  	  
When taken together, the results from the above experiments assessing peptide delivery 
into the central nervous system indicate that biotin-TAT-c29 can be successfully delivered 
to brain and spinal cord by intraperitoneal administration. In summary, biotin-TAT-c29 was 
recovered from brain lysates using pull-downs as biotin-immunopositivity was present in 
the brain using streptavidin conjugated antibodies (although background staining due to 
the endogenous biotin was also present as a confound), and while detection of biotin-TAT-
c29 in the brain was not possible using a p75NTR specific antibody (9992) due to 
coincident staining for endogenous p75NTR present in the adult basal forebrain, it was 
observed in the spinal cord. Furthermore, increased activation of ERK1/2 was observed in 
both brain and spinal cord following treatment of mice with biotin-TAT-c29. A possible 
experiment to allow direct detection of biotin-TAT-c29 in the brain using the 9992 antibody 
is through injection of the peptide into p75NTR-knockout mice, which our lab currently 
possesses. These findings add to the increasing body of work demonstrating the 
successful use of TAT-like PTDs to mediate the delivery of peptides to tissues including 
the CNS in vivo following systemic administration (Tao and Johns, 2008, Tao et al., 2008).  
 
This work also provides evidence for one of the possible mechanisms by which biotin-TAT-
c29 may act to prevent cell death. According to publications from our lab, c29 either 
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mediates its actions by enhancing Trk signalling (Matusica et al., 2013) or by acting in a 
dominant negative manner by blocking the p75NTR receptor (Coulson et al., 2000a). The 
above results indicate that biotin-TAT-c29 caused increased activation of Erk1/2 signalling 
in cells of the brain and spinal cord. According to our model, the increased signalling is 
due to enhanced activation of the Trk receptors in response to endogenous ligands. TrkB 
is the predominant Trk receptor and is expressed widely throughout most of the neurons of 
the brain (Yan et al, 1997) and was likely mediating biotin-TAT-c29’s effects In the spinal 
cord however, Erk signalling was not as strong in the TrkB positive motor neurons. 
Truncated isoforms of TrkB are known to exist in the brain and spinal cord and it is 
possible that the spinal motor neurons express a truncated isoform of TrkB which could 
mean that biotin-TAT-c29 was unable to activate Erk to similar level in the spinal cord. It is 
also possible that endogenous levels of BDNF were not sufficiently present in the 
otherwise naïve mice to trigger activation of the Trk receptors even with biotin-TAT-c29 
being present. Additional experiments in which release of endogenous growth factors are 
triggered by a relevant stimuli around the time of administration of biotin-TAT-c29 could 
test a direct correlation between the effects of biotin-TAT-c29, ligand-induced Trk receptor 
activation and extent of ERK1/2 phosphorylation. 	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Chapter	  5	  -­‐	  The	  efficacy	  of	  c29	  in	  preventing	  neurodegeneration	  
5.1.	  Background	  
In chapter 3, we established that the MPT-derived neurotrophin-withdrawal model of 
cholinergic basal forebrain death and the Aβ hippocampal degeneration model were two 
appropriate models of degeneration which could be used to test the efficacy of the biotin-
TAT-c29 peptide to be neuroprotective.  In the second model, an increase in Aβ 
accumulation in the hippocampus is induced by ablating the cholinergic basal forebrain 
neurons, a finding that has now been replicated by several independent laboratories. We 
and others have postulated that the induction of Aβ plaques due to loss of cholinergic 
innervation to the hippocampus causes a reduction in BDNF released by the 
hippocampus, which in turn promotes cleavage of APP along the amyloidogenic pathway. 
The increased production of Aβ could in turn promote neuronal toxicity via p75NTR 
(Coulson et al., 2008, Sotthibundhu et al., 2008, Yang et al., 2008, Knowles et al., 2009).. 
We therefore asked whether biotin-TAT-c29 can prevent basal forebrain lesion-induced 
plaque accumulation and toxicity in the APP/PS1 mouse model.  
 
Although we had established the basal forebrain lesion model by infusing p75NTR-SAP in 
to the ventricles, we decided to lesion the basal forebrain using a direct injection to the 
septum. Another laboratory member (Zoran Boskovic) in parallel to my work had 
established the coordinates for the direct septal lesions and this method had proved to 
minimise the variability of lesion size when the toxin was injected into the ventricle. 
Secondly, we chose to use osmotic pumps to deliver the biotin-TAT-c29 peptide, instead 
of the biotin-TAT-c29 bolus delivered by daily intraperitoneal injections.  
5.2.	  Results	  
5.2.1.	  Mini-­‐osmotic	  pump	  delivery	  of	  biotin-­‐TAT-­‐c29	  
In chapter 4, it was demonstrated that biotin-TAT-c29 could be successfully administered 
into the mouse central nervous system using intraperitoneal injections. However, the 
prolonged delivery times and the manual effort of delivery through injections encouraged 
us to explore mini-osmotic pumps as a delivery method of biotin-TAT-c29 peptide into 
mice. Using mini-osmotic pumps would allow consistent and timely administration of the 
peptide for extended periods of time without the manual labour of injections every 24-72 
hours.  
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As a pilot experiment, 7-day mini-osmotic pumps were placed subcutaneously to deliver 
an 8mg/kg dose. The effects were compared to control (scrambled peptide)-treated 
animals. The brain was analysed for effect by immunostaining for activated pERK (figure 
5.1).S 
 
 No peptide Scrambled Control (SC29) Biotin-TAT-c29 pump 
    
    
 
Figure	  5.1.	  –	  Phosphorylated	  ERK	  can	  be	  detected	  in	  the	  brain	  of	  mice	  using	  subcutaneous	  pump	  as	  a	  
delivery	  method	  	  
Bright field photomicrographs (10x) of mice implanted with a 7 day mini-osmotic pump to deliver 
8mg/kg of biotin-TAT-c29 peptide were stained using an anti phosphorylated-Erk antibody to detect 
activated Erk. No peptide control and scrambled biotin-TAT-c29 peptide were used as controls. 
Activated ERK was noted in two main areas: the septal nucleus of the basal forebrain and the 
Entorhinal cortex (n=3, Scale bars: 1mm, magnification 10x) 
 
Following 7 days of biotin-TAT-c29 treatment via subcutaneous osmotic pump enhanced 
Erk1/2 activation was observed in several brain areas. The septal nucleus again displayed 
the strongest pERK immunostaining compared to levels in naive control mice. 
Interestingly, the control peptide treatment also raised levels of ERK activation, although to 
an lesser degree that the activation induced by biotin-TAT-c29 treatment (Fig 5.1). 
Enhanced Erk1/2 staining due to biotin-TAT-c29 treatment compared to either control was 
also noted in cortical areas including the Entorhinal cortex (Fig 5.1), an area implicated in 
Se
pt
al
	  N
uc
le
us
	  
En
to
rh
in
al
	  C
or
te
x	  
αpERK αpERK αpERK 
αpERK 
αpERK αpERK 
	   72	  
learning and memory, and which is particularly susceptible to degeneration in AD. These 
results indicated that osmotic pump delivery of biotin-TAT-c29 could elicit a trophic 
response. 
5.2.3.	  Biotin-­‐TAT-­‐c29	  delivery	  into	  APP/PS1	  mice	  
At the age of 13-15 weeks, APP/PS1 mice were injected with p75NTR-saporin toxin (or 
IgG-saporin control toxin) directly into the medial septal area of the basal forebrain to 
cause a specific cholinergic neuron lesion. During the surgery, mice were also implanted 
with a subcutaneous 28-day mini-osmotic pump containing either PBS or Biotin-TAT-c29 
(10mg/kg). 28-days post surgery, animals were perfused and their brains prepared for 
histological assessment by immunostaining. ChAT postive neurons in the basal forebrain 
were counted to determine the lesion size and Aβ plaques were stained with Thiofavin S 
and the number of plaques per hippocampus were counted (Fig 5.2b).  The number of 
Aβ plaques was not significantly different between treatment groups (Fig 5.2). However 
this result is confounded by both a mixed gender of animals (Fig 5.2) and lesion sizes that 
were significantly different between groups (Fig 5.3). 
 
 
Figure	  5.2:	  No	  significant	  difference	  in	  the	  number	  of	  Aβ	  plaques	  was	  found	  between	  mice	  treated	  with	  
PBS	  and	  those	  treated	  with	  biotin-­‐TA-­‐c29	  peptide	  
Aβ plaques stained with Thioflavin S were counted in hippocampal sections. The graph represents 
the total number of Thioflavin S-positive plaques in the entire hippocampus of mice treated with 
either PBS control (n=5) or biotin-TAT-c29 peptide (n=6). No difference was seen in the number of 
Aβ plaques of the control versus the c29 treated group. Red dots indicate female mice whereas 
black squares indicate male mice. 
Number of amyloid-beta plaques per hippocampus
 
Th
io
fla
vi
n 
Po
si
tiv
e 
Pl
aq
ue
s
p7
5-s
ap
ori
n +
 PB
S
p7
5-s
ap
ori
n +
 c2
9
0
20
40
60
80
	   73	  
 
 
Figure	  5.3	  -­‐	  Loss	  of	  basal	  forebrain	  ChAT	  positive	  neurons	  with	  p75-­‐saporin	  toxin	  	  
The graph shows the average number of ChAT positive neurons in the basal forebrain region of 
13-15weeks old APP/PS1 mice with basal forebrain lesions compared to unnlesioned mice. A 
decrease in the number of ChAT positive neurons in the basal forebrain of APP/PS1 mice was 
induced by p75NTR-saporin injections. Mice implanted with a PBS-releasing pump have a 46% 
reduction in ChAT positive neurons (p=0.0015, n=5) whereas mice treated with biotin-TAT-c29 
have a 74% reduction in Chat-positive neurons (p= 0.0002, n=6). 
5.3.	  Discussion	  
The main aim of this part of my project was to investigate the efficacy of biotin-TAT-c29 in 
preventing neuronal degeneration in one or more of the mouse models developed in aim 
1. Firstly, delivery of the peptide through osmotic pumps was optimized to allow 
convenient and timely administration of the peptide. Secondly, a new method to directly 
and specifically lesion the basal forebrain was adopted. Finally, APP/PS1 mice with a 
cholinergic lesion were treated with biotin-TAT-c29 peptide to rescue Aβ plaque 
accumulation. 
 
Mini-osmotic pumps have been widely used for the delivery of peptides into the central 
nervous system (Ittner et al., 2010, Pfluger et al., 2011, Srivareerat et al., 2011). For the 
purpose of our experiment, subcutaneous mini-osmotic pumps successfully delivered the 
biotin-TAT-c29 peptide into the brain as detected by enhanced phosphorylation of ERK1/2. 
The staining was particularly obvious in the septal nucleus and the entorhinal cortex.  
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There was also a large variability noted in plaque number between groups and between 
mice. Our study used mixed cohorts of males and females, and according to our Aβ 
plaque counts, females on average appear to have more plaques (regardless of 
treatment). Literature suggests that females bear a heavier amyloid beta plaque burden 
compared to males which could explain our results being skewed due to the gender mixed 
cohorts (Wang et al., 2003, Yan et al., 2009) . As previously mentioned in chapter 3, 
APP/PS1 mice have an onset of plaque deposition at 4 months and the purpose of our 
experiment was to accelerate this plaque production by lesioning the basal forebrain and 
therefore we decided to use mice as young as 13 weeks. This could have also caused 
discrepancy in our results as the mice were extremely young and may not have begun 
accumulating plaques. Inter-mice differences could mean that some mice have a later 
onset of plaques than the others. For future experiments, the use of mice at 16 weeks 
would be ideal to allow the onset of Aβ accumulation before accelerating it. 
Although this experiment was not particularly encouraging regarding positive benefits of 
biotin-TAT-c29, a number of changes are proposed to improve the experimental design 
and thus the ability to draw conclusions regarding the effect of biotin-TAT-c29 treatment in 
this paradigm. Firstly, same sex (preferably male) mice should be used which are born 
within one week of each other and used at 16 weeks, to allow the onset of Aβ 
accumulation before accelerating it.  
 
Secondly, ideally p75NTR-saporin toxin surgery should be performed a week before the 
mini-osmotic pumps containing the peptide are implanted. Experiments performed by 
others in the lab have shown that p75NTR-saporin toxin can ablate p75NTR neurons in 
the basal forebrain as early as 7 days. This would mean that the basal forebrain could be 
lesioned independently of c29 peptide treatment.  Initiating treatment one week after 
surgery for 28 days would still allow a direct measure of the effect of c29 peptide on Aβ 
plaque accumulation. Finally, larger cohorts should be used. This would minimise the 
experimental variation in lesioning size between groups and also enable behavioural 
experiments such as Morris Water Maze or novel objection recognition to coincidently test 
hippocampal-dependent cognitive function in addition to measurement of Aβ load and 
degeneration. 
 
Although this experiment was inconclusive, biotin-TAT-c29 peptide has not only been 
neuroprotective in in vitro experiments performed during my candidature, but others in the 
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lab have found evidence for its therapeutic effects in vivo as well. Systemic treatment of 
biotin-TAT-c29 was shown to promote motor neuron survival in the SOD1G93A mouse 
model of motor neuron, mid way through disease progression, with coincident although 
transient enhanced performance on rotor rod task (manuscript submitted). In addition, 
intraperitoneal injection biotin-TAT-c29 caused enhanced long-term potentiation (LTP) in 
the hippocampus. Finally daily i.p injections of biotin-TAT-c29 have enhanced precise 
spatial memory of 6-8 months old APP/PS1 mice in the Morris water maze.  
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Concluding	  Remarks	  
The overarching aim of this study was to begin to examine the neuroprotective abilities of 
a novel candidate therapeutic peptide in neurodegenerative mouse models. Previously, 
this novel peptide (biotin-TAT-c29) had shown to be neuroprotective in vitro in: i) 
conditions of neurotrophin withdrawal and ii) protective against amyloid beta mediated 
toxicity, both of which are known features of Alzheimer’s disease. In order to test the 
effects of this peptide in vivo, models that encompasses a form of neurotrophin-dependent 
degeneration or Aβ-mediated toxicity were established. The efficacy of this peptide could 
then be tested in vivo in these Alzheimer’s disease mouse models. We also provided 
strong evidence that biotin-TAT-c29 not only crosses the blood brain within 1 hour after 
systemic administration but can mediate enhanced trophic signalling, enabling biotin-TAT-
c29 to be given as a systemic treatment rather than requiring invasive intraventricular 
infusion, or substantial modification to make it blood-brain permeable. Finally, while the 
attempt to determine the effect of c29 peptide in the Aβ hippocampal degeneration model 
was inconclusive, parallel work in our laboratory has provided encouraging evidence that 
given systemically, c29 is a promising therapeutic peptide. Nonetheless, substantial further 
work (as indicated under each aim) will be required to conclusively determine whether it 
has neuroprotective properties in models of neurodegeneration. 
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